BioTOP-Report 2010 - Berlin Partner GmbH

J o u r n a l o f B i o t e c h n o l o g y i n B e r l i n - B r a n d e n b u r g
I s s u e 40 · April 2010
BioTOP-Report 2010

Here for you. For your health.
Medical knowledge is our fascination. Together with our associates in research,
science and education we help millions of people all over the world. We are
obliged by our medical improvement, because health matters!
www.sanofi -aventis.com
AVS 903 10 022

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Content
The BioCapital Region 5
A Reputation for Excellence in Life Sciences 6
New Platform for Diagnostics R&D 10
TOP 50 Supports Technology Transfer 12
Translational Research in Regenerative Medicine 13
Successful Business Development in Biotech 14
Biotech Stands up to the Financial Crisis 18
A Place Where Big Pharma and Biotech Join Forces 22
To a Successful Partnership 24
Factories of the Future 26
Excellent Corporate Locating and Project Development Services 28
The BioCampus Network Berlin-Brandenburg 30
Biotechnology in Schools 34
Profiles 41
Addresses 57
Imprint
Publisher: BioTOP Berlin-Brandenburg
Editor: Thilo Spahl
Design & Production: supiran.de
Fasanenstraße 85 · D-10623 Berlin
Phone +49 30 318622-0
Fax +49 30 318622-22
biotop@biotop.de · www.biotop.de
Translation: Textbüro Reul GmbH · Frankfurt
Photos: p.8: World Health Summit, ATB
p.9: David Ausserhofer/MDC
p.11: Stephanie Eißrig
p.13: f650biker
p.23: José Giribás, World Health Summit
p.26: Bayer Technology Services
p.34: Stephanie Eißrig
Others: Authors or BioTOP
BioTOP is a joint initiative of the state of Berlin and the state of
Brandenburg under the umbrella of the TSB Innovationsagentur Berlin
GmbH.BioTOP is funded by the federal state of Berlin, the federal
state of Brandenburg and the Investitionsbank Berlin, cofunded by
the European Union (European Fund for Regional Development).
BioTOP coordinates the implementation of the master plan of the
health region Berlin-Brandenburg in the field “Biomedicine/Biotechnology”
3

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The BioCapital Region
Berlin-Brandenburg is one of Europe’s leading biotech regions. 25 renowned life science
research institutions, almost 200 biotech companies and more than 20 pharmaceutical
corporations conduct research here and develop new products in close and fruitful cooperation.
BioTOP has supported the development of the cluster for almost 15 years. In our
annual report, we review important developments during the past year and present an
overview of the industry.
The establishment of new platforms for in-vitro diagnostics was an especially
important achievement in 2009. In may the Center for Molecular Diagnostics and
Bioanalytics (ZMDB) was established as a flagship project of the joint Innovation
Strategy Berlin-Brandenburg. As an independent technology transfer platform that
is open to all players in the field, the ZMDB is a unique institution which connects
basic research, technology development, clinical research and industrial application.
Alongside the founding of the ZMDB, two big R&D platforms were established
with a total of 16 projects and a volume of 34 million Euros over the next five
years: the technology platform TERA Diagnostics is devoted to the development of
new biosensor systems in conjunction with terahertz technologies for signal transmission.
The aim of the Impulse Center for Integrated Bioanalytics is to integrate
all analytical process steps at the molecular level.
2009 was also an important year for a number of companies engaged in drug
development. Several innovative therapies were tested in clinical studies for the
first time: MOLOGEN completed the Phase 1 study of its immune modulator for
cancer therapy with excellent results. Silence Therapeutics started the first study
worldwide, in which siRNA is administered systemically as a cancer therapy.
NOXXON was the first company worldwide to administer a molecule of the Spiegelmer
class to humans, and Glycotope started clinical development of its glycooptimized
antibodies. Four very promising developments in Berlin that may well
shape the future of medicine.
BioTOP is proud to support this development as the central network node and your
first contact in the Biocapital region Berlin-Brandenburg. Based on our expertise,
our direct contacts with industry and academia and our extended network we are
continuously servicing the biotech industry in all questions regarding infrastructure,
financing, tech transfer, human resources and business development.
Dr. Kai Bindseil
Director BioTOP Berlin-Brandenburg
5

6
Impulse Center for Integrated Bioanalysis (IZIB)
The new Impulse Center for Integrated Bioanalysis (IZIB) is a joint
project implemented under the auspices of the Fraunhofer IBMT
and the University of Potsdam by 14 partners, including companies
from the region that form part of the DiagnostikNet-BB.
It was a prize winner in the competition „Spitzenforschung und
Innovation für die Neuen Länder“ organized by the German
Federal Ministry of Education and Research (BMBF) as part of its
regional development initiative „Unternehmen Region“ and is to
receive funds of 14 million euros by autumn 2014. The companies
involved in the project will contribute a total of 1.3 million
euros from their own funds.
The task of the Impulse Center is to analyze molecular identification
systems and replicate their functions in biohybrid or biomimetic
form. This can result in substantial analysis simplification
because the measurement itself only requires minimal effort. The
entire measurement intelligence is concentrated in the combination
of the biological identification element, transducer and
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
A Reputation for Excellence in Life Sciences
Scientific News
The exceptional research community remains a strong driving force in the development of
the Berlin-Brandenburg region as a biotech location. About half of the approximately 195
biotech companies in the region originated in universities and other academic institutions.
Among other major successes, important new project alliances were established in 2009
in the field of in vitro diagnostics. The first World Health Summit was held in Berlin, and
for the first time a European team received the international award for developing the
“Molecule of the Year”.
January 2009
p The European Strategy Forum on
Research Infrastructures (ESFRI)
includes EU-OPENSCREEN, the
European Infrastructure of Open
Screening Platforms for Chemical
Biology at the Leibniz Institute for
Molecular Pharmacology (FMP), in its
roadmap.
p Chemists at Freie Universität Berlin
identify a new active pharmaceutical
ingredient class based
on polyglycerol sulfates (dPGS) as
inflammation inhibitors.
p The Max Delbrück Center for Molecular
Medicine (MDC) receives a new
7 Tesla MRT for human diagnostics
and a 9.4 Tesla scanner for small
animals.
p Walter Rosenthal is appointed new
Chairman of the Board of Directors
of the MDC.
March 2009
p The Max Planck Institute of Colloids
and Interfaces presents a new
carbohydrate synthesizer.
April 2009
p Diana Bachran at the Charité wins
the BIONNALE Speed Lecture Award.
electronic measuring equipment. The joint projects at the center
will focus on different diseases. The main indication areas will
be infections and inflammatory as well as nutrition- and agerelated
diseases.
The Impulse Center will make insights into molecular identification
and technologies available for the development of innovative
bioanalytical processes and diagnostics and initiate new
developments in the field of bioanalytics. It is to become a leading
international research center in this field and attract the best
scientists in this and adjacent disciplines. As a communication
and translation platform, the center is to provide a focus of innovative
impulses for regional industry.
World Health Summit
The first World Health Summit took place from October 14-18,
2009 in Berlin under the heading “The Evolution of Medicine”.
International leaders from politics, industry and the scientific
community met in Berlin to discuss urgent aspects of global
May 2009
p The Center for Molecular Diagnostics
and Bioanalytics (ZMDB) launches a
platform for in-vitro diagnostics in
Berlin-Brandenburg.
June 2009
p Jan Mumme at the Leibniz Institute
for Agricultural Technology
Potsdam-Bornim is one of the winners
in the competition “Ideenwettbewerb
Bioenergie” of the German
Federal Ministry of Education and
Research (BMBF).
p The BMBF awards funds of €1.7
million to Charité – Universitätsmedizin
Berlin for the systems
biology network “ColoNET”.
September 2009
p Leif Schröder at the Leibniz Institute
for Molecular Pharmacology (FMP)
receives a €2°million research grant
from the European Research Council.
p Francesca M. Spagnoli at the Max
Delbrück Center for Molecular
Medicine (MDC) receives a €1 million
research grant from the European
Research Council.
p A joint program between Germany
and California in the field of regenerative
medicine is launched at the
initiative of the Berlin-Brandenburg
Center for Regenerative Therapies
(BCRT).

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
World Health Summit
» At the Charité, we started to build the global M8 Alliance, which is modeled on the G8, with support from the
German and French governments and in close cooperation with Université Paris Descartes. The M8 Alliance
is a group of 8 leading medical scientific centers in Germany, France, the USA, Britain, Russia, Japan, Australia
and China as well as the Inter Academy Medical Panel (IAMP), which represents 65 national academies, and the
Association of Academic Health Centers (AAHC). Our shared aim is to introduce the theme of health to the global
political agenda. The central activity of the M8 is the annual World Health Summit (WHS), which coincided in
2009 with the opening of a year of events celebrating the 300th anniversary of the Charité. This is wonderful, of
course, because the WHS follows the maxim of Rudolf Virchow: „Medicine is a social science, and, in fact, politics
is simply medicine on a grand scale.“ This comprehensive view of medicine can, in my view, be promoted best
by academic health centers like the Charité, which work in all areas of medicine, are in the vanguard of research
and are at the same time independent of lobby groups. The tremendous response to this concept from leading
scientists confirms that there is a clear need for this global initiative. The 2nd World Health Summit will take
place on October 10th - 13th, 2010, in Berlin.
health. The World Health Summit was also the first event in a year
of celebrations to mark the 300th anniversary of the Charité hospital
in 2010. Topics covered at the summit included prevention,
pandemic control, infectious diseases, access to health systems,
personalized medicine, the impact of climate change on health,
health economics and the funding of healthcare systems. Among
Prof. Dr. Frank Bier
Director
Fraunhofer Institute for Biomedical
Engineering · Branch Potsdam-Golm
p The Fraunhofer Institute for Applied
Polymer Research (IAP) builds a
new application center for polymer
nanotechnologies for € 23 million
October 2009
p The first World Health Summit takes
place in Berlin.
p The bioinformatics expert Tim
Conrad is awarded the Klaus Tschira
Prize.
p The state of Brandenburg supports
the joint research project „Technology
Platform TERA Diagnostics“ with
€10 million.
p Irene Coin at the Leibniz Institute
for Molecular Pharmacology (FMP)
receives the Junior Researcher Prize
2009 of Forschungsverbund Berlin
(FVB)
the speakers at the Summit were approximately 30 national and
international health and research ministers and secretaries of
state from four continents. Further speakers included representatives
of the World Health Organization and the Global Fund to
Fight AIDS, Tuberculosis and Malaria, CEOs from the pharmaceutical
industry and medical technology sector, several Nobel Prize
The Lab in a Hanky
» The direct molecular linkage of an identification reaction with signal generation is the ultimate
integration in bioanalytics. It means that further transduction steps or devices are no
longer needed. This is the fundamental idea behind the development of sensor-actor molecules
which is the focus of activity at the Impulse Center for Integrated Bioanalytics, an initiative of
14 research facilities and companies, most of which are located at Potsdam-Golm Science Park.
The integration of such sensory modules into everyday appliances can supply important information
directly.
November 2009
p Roland Lauster is one of the winners
of the Go-Bio competition
sponsored by the German Federal
Ministry of Education and Research
(BMBF). He receives €°3 million for
the development of a multi-organ
bioreactor in chip format.
December 2009
p Peter Fratzl, biomaterials researcher
at the Max Planck Institute of Colloids
and Interfaces in Potsdam, is
awarded the Leibniz Prize 2010.
p The European Research Council
awards a €2 million Advanced
Investigator Grant to Regine Hengge
at Freie Universität Berlin.
Prof. Dr. Detlev Ganten
President of the
World Health Summit
January 2010
p Systems biologist Nikolaus Rajewsky
of the Max Delbrück Center for
Molecular Medicine (MDC) Berlin-
Buch receives the Science Award of
the Governing Mayor of Berlin
p Christian Rosenmund and Klaus-
Peter Hofmann at the Charité receive
each a €2.5 million research grant
from the European Research Council.
p The jumping gene “Sleeping
Beauty” generated by Dr. Zsuzsanna
Izsvák, Dr. Zoltán Ivics and Dr. Lajos
Mátés of the Max Delbrück Center is
elected “Molecule of the Year 2009”
7

8
2002 Nobel Prize Laureate Sir John E. Sulston and German Federal Minister for
Education and Research Prof. Dr. Annette Schavan were among the speakers at
the opening ceremony of the World Health Summit.
Dr. Jan Mumme
Head of the APECS Junior Research
Group at the Leibniz Institute for
Agricultural Engineering
Potsdam-Bornim
www.atb-potsdam.de/apecs
winners and presidents of leading national and international scientific
bodies. The World Health Summit 2009 under the patronage
of Federal Chancellor Angela Merkel and the French President
Nicolas Sarkozy was the first in a series of annual Summits.
Molecule of the year 2009
The jumping gene or “Sleeping Beauty” transposon is “Molecule
of the Year 2009”. The transposon was generated by Dr. Zsuzsanna
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Ursula Haufe
Managing Director ipal Gesellschaft für Patentverwertung Berlin mbH
Life Science Inventions
» Berlin’s high concentration of excellent universities gives
it outstanding competence in research and science. Especially
in the life sciences we have an ever increasing number of
patent applications during the last several years. This fact suggests
enormous potential which is not yet fully realized. Most
of these life science inventions are made at the Charité, 64 in
2009. Ipal shares the goal of creating value out of these ideas,
thereby supporting the economic development of Berlin.
Biotechnology Patent Applications Per One Million Residents Per Year (2000-2005)
Berlin 15,8
Hessen 9,9
Bavaria 9,7
Baden-Wuerttemberg 8,4
Hamburg 8,1
Saxony-Anhalt 7,8
North Rhine Westphalia 7,1
Brandenburg 6,6
Rhineland-Palatinate 6,2
Thuringia 5,0
Mecklenburg Vorpommern 4,9
Lower Saxony 4,2
Schleswig Holstein 4,0
Saxony 3,9
Bremen 3,9
Saarland 3,1
Turning Agriculture into a Carbon Sink
» Global warming and the intensification of agricultural production have already resulted in a
substantial reduction in soil fertility worldwide. Biochar could be used for land restoration
because it can perform the role of natural humus to increase the sorption capacity of soil for
nutrients and water substantially. Our project APECS - Anaerobic Pathways to renewable Energies
and Carbon Sinks - aims to establish the agricultural sector as a true carbon sink, while protecting
regional materials flows.
Izsvák, Dr. Zoltán Ivics and Dr. Lajos Mátés of the Max Delbrück
Center (MDC) in Berlin, Germany. It was selected out of 15 molecules
nominated in the contest because it holds great promise for
gene therapy. This was the first time that the Molecule of the Year
has been awarded to major recipients outside the USA in Europe.
In its award citation, the jury noted that this hyperactive transposon
promises to be a revolutionary technology platform for
genetic engineering. With their new tool, the scientists were able

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Network of cooperation Berlin-Brandenburg
Deutsches Rheuma-
Forschungszentrum
Berlin
Universities
Number of joint projects
(N ≥ 3)
3
10
18
Universitätsmedizin
Berlin
Helmholtz-Association
Max-Planck-Society
Leibniz-Association
Number of projects
(N ≥ 3)
30
16
Freie Universität
Berlin
3
DRFZ
Charité
Leibniz-Institut für
Molekulare Pharmakologie
Philipps-Universität
Marburg
Technische Universität
Darmstadt
Dr. Zsuzsanna Izsvák
Dr. Zoltán Ivics
Dr. Lajos Mátés
Max Delbrück Center (MDC)
to introduce genes into cells of vertebrates which was impossible
before, as researchers previously lacked effi cient transposon
technologies to do so. However, the effi ciency of the new
transposon remained limited in some cells, such as stem cells.
The scientists solved this problem by slightly changing the genetic
code of Sleeping Beauty, resulting in a hundredfold increase in its
activity. Now, a transferred gene (transgene) fi nds its way into the
cell’s genome more easily.
FU
UM
FMP
MPI
TU
Max-Planck-Institut
für Molekulare Genetik
UP
Universität
Potsdam
LMU
MDC
Max-Delbrück-Centrum
für Molekulare Medizin
Friedrich-Schiller-
Universität Jena
Max-Planck-Institut
für Infektionsbiologie
Technische Universität
Berlin
Humboldt-Universität
zu Berlin
Max-Planck-Institut
für Molekulare
Pflanzenphysiologie
A New Tool for Gene Therapy
»
Our hyperactive Sleeping Beauty is safer, easier, and cheaper than any other
method before. Currently, scientists use disarmed viruses or a variety of
non-virus based methods to get genes into cells. However, these methods are
either too dangerous or too ineffi cient for broad application in gene therapy.
The new transposon system is able to introduce genes into cells and to stably
insert them into the cell’s genome at an effi ciency comparable to that of viral
strategies. Gene therapy strategies using Sleeping Beauty-based vector systems
could reduce the risk of insertional mutagenesis and immunogeneticity problems
imposed by viral vectors. Even after a year, the genes were still active.
UJ
MPI
MPI
The MDC researchers hope that their new tool is going to become
the new standard method to introduce genes into cells. Since
2002 the Molecule of the Year has been awarded by the International
Society for Molecular and Cell Biology and Biotechnology
Protocols and Researches (ISMCBBPR), which was founded in
2000. Prior to 2002 the award was conferred by the journal Science.
TU
HU
Ludwig-Maximilians-Universität
München
Nowhere else in Germany is the network of cooperation between research institutions as tight as in Berlin-Brandenburg. The graph shows the participation of
scientifi c establishments in the coordinated programs of the German Research Foundation (DFG) and the relations of cooperation in the life sciences established
through them.
9

10
New Platform for Diagnostics R&D
The year 2009 saw a tremendous increase in regional activities in
the fi eld of diagnostics development. Alongside the founding of
the ZMDB, two big R&D platforms were established with a total of
16 projects and a volume of 34 million Euros over the next fi ve
years: the technology platform TERA Diagnostics is devoted to the
development of new biosensor systems in conjunction with terahertz
technologies for signal transmission. The aim of the Impulse
Center for Integrated Bioanalytics is to integrate all analytical process
steps at the molecular level. In addition, eight other project
alliances were initiated in the following fi elds:
p POCT Emergency Diagnostics
p Infection Diagnostics
p Transplantation Immunology
p Hematology
p Metabolic Diseases
p Stem Cell Research
p Oncology
To enhance communication in the industry, two new conference
series were launched: the Berlin-Brandenburg Technology Forum
for In-Vitro Diagnostics and Bioanalytics, and the Potsdam Bioanalytics
Colloquium.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Berlin-Brandenburg provides exceptionally broad expertise in the fi elds of bioanalytics
and in vitro diagnostics in a large number of high-performing companies and research
facilities. In May 2009 the Center for Molecular Diagnostics and Bioanalytics (ZMDB) was
established as a fl agship project of the joint Innovation Strategy Berlin-Brandenburg. As
an independent technology transfer platform that is open to all players in the fi eld, the
ZMDB is a unique institution which connects basic research, technology development,
clinical research and industrial application. It has a clear focus on the indication areas
cancer, cardiovascular diseases, infections and immunology.
Download brochure at
www.zmdb.de/materialien/
Ralf Christoffers
Minister for Economic and European
Affairs of the State of Brandenburg
Dr. Tim Bölke
Managing Director metanomics Health GmbH and
Chairman of the ZMDB Advisory Board
Biomarkers for Diagnostics and
Drug Development
» New technologies and the trend towards personalized
medicine are opening up major growth potentials for
the diagnostics industry. At the same time, pharmaceutical
companies increasingly use innovative analytical methods to
understand the effectiveness and side-effects of development
compounds better. Metanomics Health uses its metabolite
profi ling platform to perform drug development and substantiate
food health claims on behalf of its clients – and for
its own research into biomarkers for early diagnosis. With the
Center for Molecular Diagnostics and Bioanalytics (ZMDB) in
Berlin-Brandenburg, we have established a platform which
combines our capabilities with those of many partners, especially
in science and research.
Important Pillar for
Advancing Biotechnology
» Berlin-Brandenburg is already one of Germany’s leading
locations for the rapidly growing molecular biology diagnostics
sector. The prospects for further consolidation and
extension of this market position are excellent. The Center for
Molecular Diagnostics and Bioanalytics (ZMDB) is one important
pillar for that endeavor. Its successful establishment has
created the basis for accelerated development of in-vitro
diagnostics in the Berlin-Brandenburg region.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
6
14
1
15
BIONNALE speakers 2009
7
2
8 9 12
16
3
4 5
1 Dr. Klaus Bosslet · 2 · Dr. Dominik Mumberg · 3 · Dr. Matthias Schroff · 4 · Dr. Susanne Danhauser-Riedl · 5 · Dr. Andreas Brüderle · 6 · Andreas Mietzsch · 7 · Senator Harald
Wolf · 8 · Dr. Frank Mathias · 9 · Isabella Guido · 10 · Staatssekretärin Almuth Nehring-Venus · 11 · Dr. Peter Lange · 12 · Staatssekretär Dr. Johann Komusiewicz · 13 · Beatrix
Becker · 14 · Marco Schmidt · 15 · Minister Ulrich Junghanns · 16 · Dr. Christian Wischke · 17 · Marie Weinhart · 18 · Dr. Bernd Wegener · 19 · Jean-Claude Muller · 20 · Michael
Schlenk · 21 · Dr. Kai Bindseil · 22 · Dr. Holger Hiemisch · 23 · Geert Walther Nygaard · 24 · Prof. Dr. Manfred Dietel · 25 · Dr. Sabine Sydow · 26 · Prof. Dr. Andreas Radbruch ·
27 · Dr. Metod Miklus · 28 · PD Dr. Ulrike Stein · 29 · Dr. Bernd Lepenies · 30 · Diana Bachran
20
21
25 22
24 26 27 28
10
17
18
29
23
11
13
19
30
11

12
TOP 50 Supports Technology Transfer
The research institutions in Berlin-Brandenburg region possess
a tremendous reservoir of innovative marketable product ideas.
Demand for customized support in the form of evaluation and
consulting by industry experts and the project managers in the
TOP 50 team is correspondingly high. TOP 50 shows how innovative
project concepts in academic research can be converted into
real products for the future with relatively limited resources.
Support activities focus on project ideas from regional science
institutions, which display big market potential, abut are still
at such an early stage of development that they do not yet fi nd
interest among entrepreneurial partners for R&D cooperation or
out-licensing projects. The aim of TOP 50 is therefore always to
initiate key projects to close the gap between academic research
and industrial product development.
The record to date has shown that this approach is successful. Of
a total of 64 projects identifi ed and evaluated, 39 are currently
being qualifi ed and supported by the project team. As a result of
the funding granted, ten projects are now at the proof of concept
stage, two are in preparation for company founding, and funding
decisions or the fi ling of funding applications are about to take
place for the majority of the remaining projects. The preferred
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The joint technology transfer program of Charité, Freie Universität Berlin, University of
Potsdam and BioTOP was inaugurated in mid-2008 and had a very successful year in 2009.
The aim of TOP 50 is to identify exploitable ideas and support them up the proof of concept
stage, which is when the chances of fi nding external partners or investors are considerably
better.
The Berlin universities occupy a leading position in biotechnology.
Direct R&D grants of the federal government in the fi eld of biotechnology
(2005-2007, percent of total federal biotechnology R&D grants)
Kiel 7,3
Berlin, Freie Universität 5,5
Berlin, Humboldt-Universität 5,5
Heidelberg 5,2
München, LMU 5
Göttingen 4,8
Würzburg 4
Tübingen 3,8
München, TU 3,8
Freiburg 3,6
instruments for technical development are the ZIM program of the
German Federal Ministry of Economics and Technology (BMWi) and
the Berlin ProFIT program. Building networks between scientists
and regional companies is always the main priority, but this is
successful in only about 25% of cases because the technological
gap to be closed before commercial development can begin is
often too large and must still be closed by critical experiments. As
a side-effect of TOP 50 activities, 10 new inventor registrations
and one application for orphan drug status at the EMEA were fi led
from the projects supported.
A total of 25 projects were terminated prematurely. This was either
because external experts assessed the chances for realization as
too limited due to the lack of market potential, excessive development
requirements or an uncertain patent situation or because
the TOP 50 team regarded cooperation with individual scientists
as insuffi cient. Technical qualifi cation and the development of
a project plan depend on intensive cooperation and continuous
exchange of information. If scientists are not prepared to engage
in that effort, support by TOP 50 is also inevitably of limited use.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Translational Research in Regenerative
Medicine
Regenerative medicine is a focus of development in the Berlin-Brandenburg region. The
nucleus of activities in this field is the Berlin-Brandenburg Center for Regenerative Therapies
(BCRT). In the context of the Regenerative Medicine Initiative Berlin-Brandenburg
(RMIB), researchers at the BCRT cooperate closely with about 20 companies that manufacture
regenerative medicine products themselves or provide specific services.
In recent years the significance of regenerative medicine has
increased rapidly world-wide and it has become a highly competitive
field internationally. In Germany six new centres have been
established. One of them is the BCRT, a joint facility of Europe’s
largest university hospital, the Charité, and of Germany’s leading
research organisation, the Helmholtz Association. The aim is to
use findings from basic research and bio-engineering to develop
clinical applications and products. This is possible only by crossing
the boundaries between disciplines and individual research facilities.
More than ten first-class research institutions are involved
in this research program. Key areas of research include immunology,
the musculoskeletal system and cardio-vascular diseases,
with a special focus on endogenous regeneration through the
application of cells, biological factors and biomaterials.
Arnold Schwarzenegger
Governor of California
Commenting on the Joint
German-Californian RegMed
funding program
Dr. Barbara Pfüller
represents the Berlin-Brandenburg Centre for
Regenerative Therapies (BCRT) as an „interested party“
on the Committee for Advanced Therapies (CAT) of the
European Medicines Agency (EMA)
In 2009 the BCRT initiated a Memorandum of Understanding
agreeing on a joint funding program to expand the research
and development efforts of Germany and California in the field
of regenerative medicine that was signed by State Secretary of
the Ministry for Education and Research (BMBF), Professor Frieder
Meyer-Krahmer, and the President of the California Institute for
Regenerative Medicine (CIRM), Dr. Alan Trounson. The agreement
makes it easier for researchers in California and Germany to obtain
joint funding to broaden the potential pool of expertise that can
be applied toward research in a specific area. Researchers in both
jurisdictions can apply jointly for funding through a process that
builds upon routine CIRM and BMBF procedures. For those that are
approved, CIRM is funding the California researchers and BMBF is
funding the German researchers.
There are brilliant minds all over the world
» California was the first state in the nation to support and fund stem cell research, and
now we are expanding our commitment to finding therapies for chronic diseases with yet
another international partnership. There are brilliant minds all over the world, especially here
in California, and with collaborations like this we can help ensure that potentially life-saving
breakthroughs can come more quickly and more often.
Approval of Products for Regenerative Medicine
» It is very important to involve academic and university hospital institutions
in the ongoing development of the legal regulations governing the
approval and use of advanced-therapy medicinal products (ATMPs). The Committee
for Advanced Therapies (CAT) was founded in January 2009 and prepares
a draft opinion on each ATMP application submitted to the European
Medicines Agency, consults interested parties on request, including associations
and university medical institutions, and involves them in the development
of new guidelines. University hospitals and start up’s that are developing
ATMPs can present their special concerns to CAT through the services of the
Berlin-Brandenburg Centre for Regenerative Therapies (BCRT).
13

14
Corporate Performance in 2009
Berlin-Brandenburg has Germany’s largest corporate biotech sector.
Every year, BioTOP conducts a survey of the regional cluster
to analyze current trends and present a comprehensive overview
of the industry in the database at www.biotop.de. The following
developments were determined for 2009.
The number of companies grew by one compared to the prior year
to a total of 195. Twelve companies joined the sector, including
eight newly founded enterprises and four companies that had
previously not been recorded. Eleven companies quit the regional
cluster, for reasons not directly related to the crisis, due mainly to
strategic restructuring and, in some cases, because technological
concepts proved unfeasible. The twelve new companies created
52 jobs in all. Company closures and job losses in the context of
the acquisition at Jerini AG resulted in the loss of 211 jobs. At
the same time, 186 new jobs were created in existing companies
(prior year 144).
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Successful Business Development in Biotech
The global economic crisis has now entered its second year and still continues. But to date,
the biotech industry in Berlin Brandenburg has fared better than many feared and even
proven very robust. The sector currently comprises 195 companies with a total of 3,727
employees, whereby employment stayed stable last year at a slightly higher level. The crisis
has not caused a downturn in this industry.
Commercial Development
January 2009
p Sysmex and Epigenomics AG
announce strategic R&D collaboration
in colorectal cancer diagnostics
p Scienion launches Microfluidic
sciSWIFTER – joint commercialization
with Matrical Bioscience.
p Silence Therapeutics’ partner Quark
initiates next stage of clinical trials
on DGF prevention drug developed
using Silence’s chemistry
p Revotar Biopharmaceuticals AG starts
phase II clinical trial in psoriasis
with its Bimosiamose 5% cream
February 2009
p Epigenomics AG successfully
places shares at premium in capital
increase (5.1 Mio. Euro)
p Caprotec Bioanalytics announces
the appointment of Funakoshi as
distributor for its products on the
japanese market
p Sanofi Pasteur accesses ProBioGen´s
AGE1.CR ® cell lines for various poxvectored
vaccine products under
development
March 2009
p Dr. Kai Bindseil is re-elected as
spokesman of the Council of German
Bioregions
p FDA submission of B·R·A·H·M·S MRproANP
Kryptor.
April 2009
p Epigenomics AG licenses biomarker
for development of prostate cancer
test to Predictive Biosciences
p Bayer Crop Science closes research
facility in Potsdam
p Winthrop Arzneimittel GmbH, a
subsidiary of sanofi-aventis, moves
from Cologne to Berlin
After six years of employment growth by 3.5 % annually on average,
the year 2009 ended with positive zero growth. In view of
the difficult economic environment, this is an impressive sign of
stability and confirms that the industry is now firmly established
and more resilient to economic turbulence than the market as a
whole.
With eight new companies, founding activity remained at the
level of the preceding years. Business models, too, followed the
established trend. As before, newly founded companies tend to
be smaller firms with 1-10 employees focused predominantly on
service-oriented business models rather than capital-intensive
product developments. The prime reason is that too little venture
capital is available for the industry as a whole – and especially for
founding new companies.
p Invitek Gesellschaft für Biotechnik
& Biodesign mbH, Berlin is acquired
by the STRATEC Group, Germany.
May 2009
p TheraCode GmbH acquires JPT Peptide
Technologies GmbH
June 2009
p MOLOGEN uplisted to the Prime
Standard of Deutsche Börse
p NOXXON announces initiation of
first clinical trial with a Spiegelmer
® (NOX-E36 for the treatment
of inflammatory kidney diseases
including diabetic nephropathy)
p Silence Therapeutics receives
approval to initiate Phase I clinical
trials on Atu027 for treatment
of patients with advanced solid
tumours
p DSM acquires the Berlin based
biogas specialist Biopract
July 2009
p JPK Instruments opens offices in
Japan
p Revotar to initiate phase IIa study of
bimosiamose to support development
in COPD
August 2009
p BIOTECON Diagnostics GmbH and
BIOTEST AG start worldwide sales
cooperation
p Silence Therapeutics signs siRNA
delivery collaboration with Dainippon
Sumitomo Pharma
September 2009
p B.R.A.H.M.S launches new blood
test for acute myocardial infarction
based on a copeptin assay
p Human BioSciences starts construction
of ist new production facility in
Luckenwalde

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Deals and Product Developments
Biotech companies in Berlin-Brandenburg achieved major milestones
in product development and in the establishment of cooperation
projects in a year that was also shaped by three takeovers.
Below, we present some examples from the broad range of corporate
activities in 2009:
B.R.A.H.M.S AG in Hennigsdorf was acquired by Thermo Fisher Scientific
for 350 Mio Euro. B·R·A·H·M·S is Germany’s third largest
biotech company and owns several hundred patents with a focus
on innovative biomarkers. Thermo Fisher Scientific announced
that a European Center of Excellence for clinical diagnostics with
a focus on innovative biomarkers is to be established in Hennigsdorf.
Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin was
acquired by the STRATEC Group, Germany. In terms of the STRATEC
Group’s corporate structure, Invitek will be incorporated under
p Revotar Biopharmaceuticals AG
receives 2.5 Million euro research
grant
p RiNA GmbH and 5 PRIME take over
Roche’s RTS protein expression
portfolio
p PCRFast ® Stool Diagnostics of ifp
Institut für Produktqualität will
be marketed and distributed in
Germany by bioMérieux
October 2009
p NOXXON Pharma AG announces
excellent preliminary phase I trial
results for
p Spiegelmer ® NOX-E36
p Epigenomics AG launches its Epi
proColon product in Europe - the
first ever in vitro diagnostic blood
Montserrat Vendrell
Directora General
Biocat – BioRegió de Catalunya
test for colorectal cancer early
detection
p Thermo Fisher Scientific acquires
B.R.A.H.M.S Aktiengesellschaft for
EUR 350 Mio.
p InVivo and CEVEC pharmaceuticals
sign license agreement regarding
the use of human CAP-T Technology
for production of recombinant
proteins
November 2009
p Glycotope GmbH has received
regulatory approval by German and
Italian regulatory authorities for a
Phase I study of Glycotope´s lead
antibody GT-MAB 2.5-GEXTM for the
treatment of various solid cancers.
p caprotec bioanalytics opens US subsidiary
in Burlington, Massachusetts
The view from abroad
» Within the European biotechnology
scene Berlin-Brandenburg is perceived
as a ‘mature cluster’ offering a wide range
of services and instruments to strengthen
the local Life Science sector and possessing
a competitive infrastructure for business
and research – an excellent starting point
for joint projects and initiatives with other
regions to benefit from the opportunities
that Europe has to offer.
the wholly-owned subsidiary Robion AG, Switzerland. STRATEC
expects cooperation with the highly-qualified Invitek Team
in Berlin in the development of molecular biological applications
and a shared strategic focus to generate additional growth
potential in this future market. Berlin based Biopract GmbH was
acquired by Royal DSM N.V., the global Life Sciences and Materials
Sciences company headquartered in the Netherlands. The acquisition
serves as an entry point for DSM into the promising biogas
market, which is showing 15-20% growth per year.
Epigenomics AG, a molecular diagnostics company focusing on the
development and commercialization of in vitro diagnostic (IVD)
products for cancer, launched the world’s first in vitro diagnostic
blood test for early detection of colorectal cancer. Epi proColon
is an innovative molecular diagnostic test that can detect tumor
derived methylated DNA of the Septin9 gene (mSEPT9) in blood
plasma as a reliable indicator, or biomarker, for colorectal cancer.
p HC Berlin Pharma is starting a
field study for antimalarial drug
ArTiMist
p MicroDiscovery and Bayer Schering
Pharma renew their successful
cooperation in the field of bioinformatics
p MOLOGEN applies for clinical study
with cell-based gene therapy for
renal cancer and reaches primary
end points in MGN1703 study.
p Attomol launches new Real-Time-
PCR-technology
p NOXXON announces initiation of
first-in-human clinical trial with
hematopoietic stem cell mobilizing
Spiegelmer ® NOX-A12
p MagForce Nanotechnologies reaches
primary study endpoint in pivotal
glioblastoma study
December 2009
p ProBioGen receives Innovation
Award Berlin-Brandenburg
p MagForce Nanotechnologies AG
appoints Dr. Peter Heinrich as Chief
Executive Officer
p Eckert & Ziegler: capital increase
successfully concluded / clear oversubscription
(21,5 Mio. EUR)
January 2010
p Silence Therapeutics announces
completion of merger with Intradigm
Corporation and issue of new
shares (17 Mio. EUR)
15

16
Dr. Steffen Goletz
CEO/CSO
Glycotope GmbH
Scienion AG and Matrical Bioscience, Washington launched the
sciSWIFTER. It will be jointly commercialized by Scienion AG and
Matrical Bioscience, both leading suppliers in the life science
market. The time and reagent saving drop on demand dispenser,
can dispense up to 16 different substances in parallel into various
multi well plate formats. Dispense range is 100 pl - 100µl with
dead volumes close to zero. Each nozzle has online-drop-control
and optical volume determination.
NOXXON Pharma AG announced successful completion of the first
phase I trial with its anti-inflammatory Spiegelmer ® NOX-E36.
This drug candidate will be developed for the treatment of complications
of type 2 diabetes, preferentially diabetic nephropathy,
but also others. In November NOXXON started dosing of healthy
volunteers in a first-in-human clinical trial with hematopoietic
stem cell mobilizing Spiegelmer ® NOX-A12.
MOLOGEN AG has reached the primary objectives of the phase 1b
clinical study with the cancer drug MGN1703. Toxicity, i.e. serious
intolerability, that would limit the dose has not been found.
MOLOGEN will therefore be able to use the maximum dosage of 60
mg twice a week in the planned phase 2 clinical study, which was
approved early in 2010.
Glycotope GmbH, Berlin, has received regulatory approval by
Germany and Italian regulatory authorities for a Phase I study
of its lead antibody GT-MAB 2.5-GEX for the treatment of various
solid cancers. The approvals further underline the suitability
of Glycotope´s proprietary GlycoExpress technology for the
improvement, glycooptimization and high yield production of
therapeutic proteins for the use in humans.
Silence Therapeutics received approval to initiate phase I clinical
trials on Atu027 and started dosing in June. The trial is being
conducted at the clinical study centre of the Cancer Hospital
SanaFontis in Freiburg, Germany as an open-label, single-centre,
dose-finding Phase I study in patients with advanced solid
(malignant) tumours. In December Silence agreed to buy the US
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Second Generation Antibodies
» 2009 has been extremely successful for Glycotope. With the approval of our development platform GlycoExpress
and the onset of clinical phase I for our proprietary antibody GT-Mab 2.5-GEX, we are highly excited to
see the enormous pre-clinical effects of our core technology for optimizing a protein´s glycosylation now as well
in the clinic. Further, we have completed the development of our first 2nd-generation antibody CetuxiMab-GEX
and are expecting to start trials in Q3/2010. Finally, following our move to new premises within the campus in
Buch and with the support of the BBB, we are happy that we could largely expand our lab- and office-space for
our now more than 70 employees just in Berlin to successfully proceed with our projects.
Employees in Biotech SMEs
Number of employees
4000
3500
3000
2500
2000
1500
1000
500
0
1.305
1.840
2.359
3.164
2.942
96 98 00 01 02 03 04 05 06 07 08 09
With 3,727 employees employment stayed stable over the year. The number
of companies rose to 195, reflecting the arrival of twelve companies
(8 of which were newly founded) and eleven departures. (Source: Internal
survey, BioTOP database, 195 companies questioned, February 2010)
company Intradigm Corporation in a share-swap deal worth $26
Million.
The biotech company Human BioSciences invested 40 million euros
in a new production plant in Luckenwalde (Teltow-Fläming). The
enterprise will manufacture collagen-based bandages and bandaids
for chronic wounds and will create 100 jobs. The company’s
products are also used in cosmetics and cosmetic medicine.
3.007
3.003
3.213
3.427
3.590
3.700
3.727

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Market Segments of Companies
Number of companies
180
160
140
120
100
80
60
40
20
0
15%
24 29 33 30 33 35 26 29 30
01 02 03 04 05 06 07 08 09
Agriculture/Food
25 27 22 26 30 30 28 27 36
01 02 03 04 05 06 07 08 09
White Biotechnology / Environmental Biotechnology
Most companies focus on biomedicine. A total of 84% of companies, focus primarily on development in the areas of new diagnostics, drug development and
associated services or technologies. 15% of the companies are active in the agriculture / food sector, white biotechnology / environmental biotechnology
increased to 18% of all entries. (Source: Internal survey, BioTOP database, responses from 195 companies, multiple entries, February 2010)
Number of Employees according to Company Size
Number of employees
1.700
1.600
1.400
1.200
1.000
800
600
400
200
0
610
98 99 00 01 02 03 04 05 06 07 08 09
115 companies 1-10 employees
18%
98 99 00 01 02 03 04 05 06 07 08 09
65 companies 11-50 employees
84%
108 113 122 109 134 132 155 165 163
01 02 03 04 05 06 07 08 09
Biomedicine
98 99 00 01 02 03 04 05 06 07 08 09
15 companies > 51 employees
In comparison to the previous year, the average payroll per company got reduced by 15% in the 1-10 category and by 7% in the 11-50 category. The average
number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 195 companies questioned, February 2010)
1394
1723
17

18
Despite major cause for concern, the biotech industry has proved
far more resilient to the financial and crisis than other sectors.
Not a single biotech company in Berlin-Brandenburg had to close
down in 2009 as a result of the crisis. That the industry is less
dependent on general economic trends is due to stable demand
on the health and research markets, which needs to be met continuously.
In addition, activities in this strongly research-focused
sector are largely financed by stable budgets which are affected
less directly than the investment goods industries by turbulences
on the private capital markets.
This may be the reason why the majority of regional companies
that participated in a BioTOP survey do not anticipate a decline
in sales and expect the biotech industry to fare better than the
market as a whole. This positive business climate in the region
was also confirmed in another survey conducted by the industry
association BioDeutschland.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Stands up to the Financial Crisis
Dr. Matthias Gerhardt
Managing Director DSM Biopract GmbH
www.dsmbiogas.com
The overall economic situation could hardly be worse: a global economic downturn, a
continuous decline in VC investments and a very problematic environment for innovative
companies. But the mood in the industry and its economic performance are nonetheless
better than expected.
This positive impression is nonetheless surprising, considering the
situation on the capital markets. In Germany VC investments have
been in decline for five years in succession. According to a survey
among a panel 38 leading VC investors by Fleischhauer, Hoyer &
Partner, VC investments in Germany dropped from €565 million
in 2008 to €341 million in 2009 (panelists only) – a reduction
by 40%. Most venture capital went to the software industry (€71
million), internet (€47 million) and biotechnology (€46 million).
About one quarter of investments were made in Bavaria, followed
by North-Rhine Westphalia (15%) and Berlin (13%).
The private equity industry finds itself in a very difficult period.
That is also reflected in current figures from the European industry
association EVCA. Total losses rose by the factor 3.5 to €3.2 billion,
while the number of new fund launches fell by 40%. Although
these figures relate to all industries, the downward trend was
naturally also felt in the biotech sector. It is therefore not astonishing
that 49% of VC investments covered by the above-mentioned
panel study were publicly funded. And, much to the benefit
of the region, most of these public investments came from IBB
Beteiligungsgesellschaft Berlin.
Focus on the Biogas Market
» DSM New Business Development regards the biogas market segment as especially important
and has therefore set up its DSM Biogas division. It is evident that bioenergy in general has
tremendous growth potential. Although public debate often focuses on biofuels, biogas will play
a key role in the future because it is in energetic terms the most efficient method of biomassbased
energy generation. This sector is currently growing by 15 to 20 percent annually. At DSM
Biopract, we are now developing the second generation additives for this market together with
our enzyme specialists, in particular at DSM Food Specialities. These additives are enzyme complexes
that perform many different activities and therefore support effective depletion of plant
biomass with higher yields and depletion speeds.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Leo W. Tristram
Managing Director of RiNA GmbH
and Dr. Manfred Baier (on the left)
Head of Roche Applied Science
Overall, the analysis shows that, with only few exceptions, access
to venture capital remains closed to biotech companies. Matters
are even worse as regards debt financing from banks. For
the biotech industry, bank funding was always hard to procure.
Now, however, the more stringent lending requirements imposed
in the context of the financial crisis make it unlikely that financings
for biotech companies, which usually entail certain risks, will
Products for cell-free biosynthesis
» In September 2009 we signed a contract with Roche Applied Science on
the transfer of the complete RTS Protein Expression portfolio to RiNA GmbH.
The RTS cell-free expression kits ideally complement the already existing RiNA
product portfolio and its dedicated specific customer service for cell-free biosynthesis.
Together with 5 PRIME (exclusive partner) products for purification
and detection of recombinant proteins the RTS technology will form a strong
basis for joint development of innovative products in this dynamic field.
be forthcoming even in the longer term. Ambitions to go public,
which was the most promising financing method in the past, are
currently not entertained in the industry.
In terms of equity funding, Berlin-Brandenburg is well positioned
with IBB Beteiligungsgesellschaft and BC Brandenburg Capital.
Together, they stand for a fund volume of €80 million. The will
19

20
Michaël de Mari
CEO · Human BioSciences GmbH
Production in Luckenwalde
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
» We started planning our production plant in Luckenwalde in 2009. In April 2011, we will start manufacturing
collagen-based products for modern wound care and cosmetics with some 100 employees here. Alongside
Maryland, USA, and Taiwan, Luckenwalde is the third production location for products developed by the US company
BioCore Inc. The Biotechnology Park at Luckenwalde provides us with an excellent infrastructure and perfect
conditions – for new product developments in the future too.
New Production Plant of Human BioSciences in Luckenwalde
to invest is strong, and there is also no lack of funding requests.
What acts as a brake on investments is that both state funds are
co-financed by the European Regional Development Fund (ERDF),
so that a private lead investor is usually needed. And they are
presently rare.
Many SME who are denied access to the capital market have simply
vacated that terrain and focus their business models on services,
industry contracts and research alliances. No major VC financing
consequently took place in the region in 2009. There was not a
single VC investment in the eight new companies founded during
the year. The situation appears slightly better for exchange listed
companies, which were able to attract €50.1 million through
capital increases and can therefore continue to develop their R&D
pipelines.
Government therefore remains a prime source of funding for the
implementation of new development projects in biotech companies.
Together, the two federal states Berlin and Brandenburg
alone have approved more than €67 million in support funding
for R&D and infrastructure projects in the life sciences sector.
The funding program ZIM under the federal government’s Economic
Stimulus Package II has played a key role as a driver of new
development projects. Since the program was launched in July
2008, €834 million were approved for all technology sectors, of
which more than €118 million went to the region Berlin-Brandenburg.
Some €95 million were approved for the life sciences.
Especially in the current period, support funding for the development
of new products is immensely important. Since the financing
situation will not change in the short term, it is all the more
important that government continues to support the industry.
And not only by direct funding is needed, but also improvements
in the conditions for financing and advancing innovation. The
present tax laws place highly innovative companies at a disadvantage
in international comparison and deter investors. The
industry association BIO Deutschland has identified the key problems
and launched an initiative to improve that situation.
Despite strong support from the public sector, it will be vital for
the growth of the industry in the medium term to attract more
private capital into the biotech industry again.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
New Biotech Companies
3B Pharmaceuticals
GmbH
3b-pharma.com
Astra Biotech GmbH
astrabiotech.de
bbi-biotech GmbH
bbi-biotech.com
BioRepro GmbH
biorepro.com
breecon GmbH
breecon.com
Metabolomic
Discoveries UG
metabolomicdiscoveries.com
mfd Diagnostics GmbH
mfd-diagnostics.com
nanopartica GmbH
nanopartica.com
novojoint
novojoint.de
opTricon Entwicklungsgesellschaft
für optische
Technologien
optricon.de
ProteaImmun GmbH
proteaimmun.de
3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical
R&D company based in Berlin, Germany. The company is
dedicated to the development of peptide-based pharmaceutical-
and diagnostic products. 3BP is pursuing projects in hemophilia
and nuclear medicine.
The Company Astra Biotech offers a wide range of high-quality
reagents and diagnostic kits. The catalogue provided by our
company includes reagents for detecting of human hormones,
genetic diseases, tumor markers and allergens. Besides, we
develop cutting-edge, technologically perfect solutions in the
field of diagnostics and we are ready to offer our experience,
skills and knowledge for realization of your projects.
In the focus of the activities of bbi-biotech lie systems for the
sterile sampling from bioreactors for all applications in the
biotechnology, pharmaceutical, food, cosmetics and chemical
industry. In addition, bbi-biotech develops components - in
especially disposable ones - for the preparation of a new generation
of fermentors and bioreactors and offers consulting and
planning services for biotech projects, its implementation and
services.
BioRepro is the first pharmaceutical company, whose core competency
is the breeding of leeches under controlled laboratory
conditions for medical therapies. We concentrate on the
establishment of GMP breeding procedures and will be able to
provide leeches with standardized quality while equally allowing
scalability to supply medical demand. Additionally, through
the re-initiation of fundamental research, we will gain deeper
understanding of further potential in medical and cosmetic
treatment areas.
The breecon GmbH is an innovative service company in life
science with focus on green biotechnology. The objectives of
the company are consulting, application and mediation of
biotechnological-analytical services as well as their development
and marketing. The breecon GmbH offers his services to
plant breeders and companies of the industrial biotechnology
and supports the utilization of genetic diversity in the context
of SMART breeding.
Metabolomic Discoveries is an analytical service and research
company. We provide mass spectrometry based metabolite profiling
and fingerprinting of biological material, as well as single
compound measurements.
The mfd Diagnostics GmbH (BT Luckenwalde) is a life science
research and development company for diagnostic and therapeutic
application of innovative laser technologies. The main
advantages of the developed technologies are the non-/
minimally-invasive measurement methods, the non-artificial
approach and the possibility of real-time measurement. Therefore,
those are promising tools for the diagnosis and therapy
monitoring in the neurological practice and in the perinatal
surveillance.
Nanopartica GmbH optimizes existing products of other companies,
but is also developing new products and materials. In
particular, companies in surface-, bio-, and medical-technology
can benefit from nanopartica. By means of functionalized
polymers, we can encapsulate guest molecules (drugs, dyes,
vitamins), particles (gold, silver, platinum), or ions. This will
indirectly change the guests’ properties and expands its scope.
R&D of a new therapy approach for the treatment of severe,
inflammatory diseases of the joint and for the support of
wound healing after injuries of the skin and bones in man as
well as animals. The concept is based on the development of
smart gene constructs, which allow the inflammation controlled
release of suitable therapeutic proteins at the site of damage/
repair. We aim to provide our therapy for three target markets:
1. Small Animal Clinics, 2. Equine Clinics, 3. Human Medicine
opTricon develops and produces mobile readers for quantitative
analyzes of Immunoassays for Point-of-Care-diagnostics, especially
Lateral Flow Assays (LFA). Additional business segments are
components and Systems for signal transmission and sensors
for lbioanalytics. opTricon develops the devices in partnership
with the customers and works as OEM-suppliers and is certified
by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and
EN ISO 9001:2008.
ProteaImmun GmbH offers human proteases, ELISA, enzyme and
antibody. ProteaImmun’s expertise in the recombinant protein
expression, especially in human proteases and in the development
of antibodies and modern methods of detection and
analysis of proteins, enables us to offer customized solutions
and support with single components as well as with complete
molecular diagnostic systems.
Financing and Added Value
VC Fonds Technologie
Berlin
Venture Capital
for companies in Berlin
IBB Beteiligungsgesellschaft mbH offers equity fi nancing
for high tech companies in Berlin. For our fund
VC Fonds Technologie Berlin (€52m) we are looking
for investment opportunities in the biotechnology and
medical technology sector.
Our investment approach is based on hands-on
invol vement and active management support for
each portfolio company, delivered by our highly experienced
investment team. VC Fonds Technologie Berlin
not only provides capital, but also helps execute the
business plan.
Are you interested? Please do not hesitate to contact us.
IBB Beteiligungsgesellschaft mbH
Mrs. Ute Mercker / Mr. Christian Seegers
Bundesallee 171
10715 Berlin / Germany
Phone: +49 (0)30 2125-3201
www.ibb-bet.de
Selected portfolio companies:
VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank
Berlin (IBB) and the State of Berlin. It is co-fi nanced by the European Regional Development
Fund (ERDF).
21

22
A Place Where Big Pharma and
Biotech Join Forces
Berlin is one of the birthplaces of the modern pharmaceutical
industry. In 1851 Ernst Schering opened a pharmacy he named
Grüne Apotheke (green pharmacy). Twenty years later, the founder
incorporated the business as a stock company, which later became
Schering AG. In 2006 the company was taken over by Bayer. Since
that merger took place, the health sector has become an important
area of business for Bayer. In 2008, sales by its health division
grew by 4.1 percent to 15.4 billion euros and accounted for
almost half of total group sales. 10.7 billion euros came from the
pharmaceuticals business, i.e. Bayer Schering Pharma. Today the
company concentrates on four core areas: Oncology, Cardiology,
Women´s Healthcare, and Diagnostic Imaging. The second biggest
pharmaceutical company in Berlin is Berlin-Chemie. The company
was founded in 1890 and is today the German subsidiary of the
Italian MENARINI group.
Grants for Targets
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The development of the biotech industry in Berlin-Brandenburg has benefited from the
geographical proximity of major pharmaceuticals companies. The region has now become
a leading biotech location, which in turn makes it attractive for other pharmaceuticals
companies.
In order to further pool expertise and to join forces for mutual
benefit, Bayer Schering Pharma AG is supporting collaborative
research projects on attractive, novel molecular targets in the
fields of
p Oncology
p Cardiology
p Gynecology
p In vivo Imaging
To promote this new approach, Bayer Schering Pharma AG
intends to allocate grants for the further development of
promising targets. The size of the individual grants depends
on the target specifics and the phase of development. Grants
vary accordingly and are limited to a maximum of €250,000.
Researchers from universities, other academic research institutes
and start-up companies from all over the world are eligible
to apply.
For more information, see www.grants4targets.com
It employs more than 4,350 people, around 1,920 of them in
Germany and occupies a leading position among pharmaceutical
companies in Central and Eastern Europe. Berlin-Chemie markets
prescription drugs and OTC preparations. The product portfolio
includes a broad spectrum of therapeutic agents for office-based
doctors and for clinics.
Alongside Bayer Schering Pharma, Berlin-Chemie and some 20
mid-sized companies, other international corporations have
extended their presence in Berlin. In 1984 the US Bausch & Lomb
Group bought the Berlin ophthalmics manufacturer Dr. Mann
Pharma. The company now employs more than 700 people in
Berlin and is expanding its operations here. In 1995 Altana built
a new pharmaceuticals factory in the Brandenburg town of Oranienburg,
north of Berlin. In 2006 Altana was sold to the Danish
Pharma R&D is on the Upswing in Germany
p German R&D Employees (Thousand)
p R&D Expenses (Billion Euros)
14,1
2,76
14,3
3,01
14,1
3,08
14,3
3,36
14,5
3,61
14,5
3,90
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
R&D expenses and R&D employees in the german pharmaceutical industry
(members of the german association of research-based pharmaceutical
companies (VFA))
14,5
3,95
15,7
4,16
16,8
4,37
17
4,53
17,1
4,84

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Andreas Fibig
Chairman of the Board
of Management of
Bayer Schering Pharma AG
company Nycomed. Today Nycomed Germany operates two stateof-the-art
production units covering 36,000 sqm in Oranienburg.
In early 2000 the French pharmaceuticals corporation Sanofi-
Synthelabo, formed by merger, moved its German headquarters
from Munich to Berlin. After the merger of Sanofi and Aventis in
2004, the company that is now the world’s third largest pharmaceuticals
group expanded its operations in Berlin to include marketing
and sales and now employs around 1,900 people in the
German capital. In 2008 pharmaceutical group Pfizer Inc moved
its German headquarters to Berlin from Karlsruhe to be in the
vicinity of the federal capital’s growing health-related industry.
Shortly afterwards, the company announced that Berlin will also
be the location of Pfizer’s European oncology business unit. Pfizer
is currently conducting 20 clinical studies in cooperation with
Charité and the Helios Clinics.
Industry and academia are closely interconnected. Chris Viehbacher, CEO of
sanofi-aventis, and Prof. Karl Max Einhäupl, Chairman of the Executive Board
of Charité - Universitätsmedizin Berlin, at the opening press conference of the
World Health Summit.
Berlin can become Germany’s Pharmaceuticals Capital
» Berlin has developed very well. The German capital attracts many talented people. Berlin’s
science landscape has evolved rapidly too, making the city one of Europe’s leading sites
for science and research. For Bayer Schering Pharma, networking with partners in science and
research has always been essential. That is why Berlin is such an attractive location for us. The
city is home to many academic institutions. We cooperate closely with researchers both at the
Charité and in biotech companies in Adlershof and Berlin-Buch. We want to support the development
of small companies in the region so that it acquires the necessary critical mass. Berlin
can become Germany’s pharmaceuticals capital.
In 2009, Berlin-Brandenburg was again strengthened considerably
as a pharmaceuticals region by the relocation of the German
operations of Shire AG to Berlin and by the takeover of Wyeth by
Pfizer, which was followed by the relocation of the company’s
German branch to Berlin. Sanofi-aventis decided to merge the
generics and OTC business of its subsidiary Winthrop and the former
activities of sanofi-aventis in the field of unpatented products
at its Berlin site. The aim of the new „Commercial“ division is
to enhance the position of both companies on the German market
under preservation of the ’Winthrop’ brand and of Winthrop
Arzneimittel GmbH as a pharmaceutical manufacturer.
Federal Labor and Social Affairs Minister, Ursula von der Leyen, and Dr. Reinhard
Uppenkamp, CEO of Berlin-Chemie AG – Berlin-Chemie AG participates in
the vocational training initiative „Ausbildung jetzt“ and has received repeated
awards from the Chamber of Industry and Commerce (IHK) as an exemplary
provider of vocational training. The company is committed to improving
professional opportunities for young people. Berlin-Chemie also operates a
protected workshop where 34 people with physical and mental disabilities
receive care and therapy and can engage in meaningful activities.
23

24
A company like sanofi-aventis – being one of
the world’s largest pharmaceutical companies –
is very interested in creating partnerships worldwide. Especially
in biotechnology, as pharmaceutical business and biotechnology
business simply belong together.
Prosperous tradition
Establishing and maintaining good partnerships is important to
sanofi-aventis, as the company has a long tradition of a successful
integrated international network of core partnerships. Large
companies, small biotech companies and academic institutions
are all involved. Each possesses specific strengths and abilities.
And the cooperation between the partners is paying off – especially
or even if they come from two different worlds. Pharmaceutical
research is a very complex field, where small and flexible
research units in particular can make a large contribution.
Strong together
Not only, but also, through our partnerships, we are and remain
at the cutting edge of international research and can identify and
use the latest results of modern medicine. We are absolutely convinced,
that international cooperation is main pillar of successful
research and development. We can contribute significantly to
medical research by connecting various expertises – for the benefit
of our patients, our partners and our company.
Trust and respect
Partnership means having shared visions. Therefore, important
partnerships are designed long term and are based primarily on
two things: trust and mutual respect. The creative structure of our
cooperation contributes to this - always considering both partners’
goals and demands. A partnership is much more than a
mere signing of a contract. Our goal is a real partnership in which
both sides can develop and be successful. The focus is always on
the project and good cooperation at all levels between research
groups, departments, division management and company management.
Important requirements for each partnership are that it
matches our strategy and our corporate culture.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
To a Successful Partnership or Shared Visions
When two people get together and plan a common future, this should ideally lead to a
partnership both benefit from. Such a win-win situation does not only exist in private life
– it is also one impetus of a successful partnership between companies. The size of a company
is not the decisive factor. In particular, small businesses, universities and research
institutes have a lot to offer and are therefore interesting partners for Big Pharma.
Peter Guenter
General Manager Commercial Operations Germany
Sanofi-aventis
Triangle – research, technology and marketing
Sanofi-aventis has a lot to offer to its partners. Not only a wide
spectrum of pharmaceutical research, knowledge of new therapeutic
approaches and resulting developments are part of our
strengths. But also their technical implementation. Our extensive
experience makes us an attractive partner, when it comes to combine
research with technical know-how and convert them into
successful production and products. And last but not least, our
knowledge in marketing plays a decisive role in business partnering.
This triangle of research, technical implementation and
global marketing and sales units makes us interesting for many
partners. Globally, we work together in all phases of the value
chain - from research to development and production to marketing.
Search for new partners – national and global
We are always looking for new partners with creative ideas. An
example of this successful search is our “Partnering Day” with
biotech companies in Berlin-Brandenburg in April 2009. The
result of this 2-day meeting with many biotech companies was a
series of promising contacts, of which some are currently becoming
concrete. Our continuous monitoring of interesting biotech
companies - as we are doing in this region for example – will
most likely lead to further partnerships.
Our motivation
Looking at it globally, at least a fourth of our successful drugs have
been developed in partnerships. This demonstrates that we confidently
and successfully work with external partners for the benefit
of patients. This motivation defines our partnerships – both
now and in the future.
Contact
ideen@sanofi-aventis.com
sanofi-aventis.com

Spot an für die besten Ideen
aus Deutschland!
365 Erfolgsgeschichten, die unser Land begeistern.
Die Deutsche Bank und die Initiative „Deutschland – Land der Ideen“ präsentieren die Sieger des Wettbewerbs „365 Orte im Land der Ideen“. Ob es um
Biotechnologie, Karriereförderung, Innovationsmanagement oder Nachhaltigkeit geht: Alle „Ausgewählten Orte“ zeigen in verschiedenen Kategorien,
wie Erfolgsgeschichten made in Germany mit Know-how und Leidenschaft unsere Zukunft gestalten. Entdecken Sie Deutschlands einzigartiges Netzwerk
für Mut, Neugier und Innovation!
Zum 20-jährigen Jubiläum der Wiedervereinigung prämieren wir jeden Monat eine Idee, die sich mit Engagement und Kreativität für das vereinte
Deutschland einsetzt, zusätzlich mit dem Sonderpreis „Gelebte Einheit“.
Applaus für Deutschlands Zukunftsmacher!
150-1471_060306_AZ_Biotech Alle Sieger auf www.deutsche-bank.de/ideen
08.03.2006 13:02 Uhr Seite 1
210x148_5_LDI_Phase 2_032010_intern.indd 1 05.03.2010 10:56:45 Uhr
Promotion and Financing for Bio-Tech Firms
Are you a technology-based firm in the bio-tech branch, and are you planning to invest
in the State of Brandenburg? We can support your project with grants, loans at reduced
interest rates and risk and equity capital. Just contact us!
InvestitionsBank des Landes Brandenburg
Phone: +49 331 660-1256 · E-mail: technologie@ilb.de · www.ilb.de

26
Factories of the Future
High throughput times in development, planning and the installation
of manufacturing premises are still common in today’s
business. However, they do not stand in accordance with the
necessity to comply with volatile market prognosis or to react on
changing market situations on short notice. It must be constituted
that the time to market and the scalability of production
processes are critical key success factors in the global business.
This is in particular valid for the Biotech industry. Small, modular
units which are easy to install and thus can be quickly brought
into operation, could provide the appropriate solution for these
challenges. But it is not only the development sector which can
benefit from the new approach, making broader use of small unit
based micro reaction technology. In the lifecycle of a product,
this new technology also enables the industry to easier adapt
the ‘product manufacturing’ scale to the next higher level. This is
made possible through the provision of pre-manufactured standard
units which only must be assembled according to customers
need. Finally this can lead to advantages in each of the areas:
planning, purchasing, installation and the start-up of a new production
facility. Using a highly flexible plant layout also means to
have a low investment risk.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Global competition in the chemical and biochemical industry is continuously increasing.
Subsequently the importance to substantially reduce the effort and investments necessary
for the development of new technologies and (bio-) chemical products as well as pharmaceutical
drugs is growing at the same time. Already today one can dare to say that an
advantage in this area can decide on the success or failure of an innovative product. In
addition, a clear trend can be observed towards highly specialized and highly individualized
products, which in the medical arena are also known under the headline ‘personalized
medicine’ and which typically are produced only in small amounts and small lots.
Dr. Helmut Mothes
Member of the Executive Committee and
Head of Division Process Technology of
Bayer Technology Services
With the foundation of INVITE in North Rhine Westfalia the first
step is made and the environment is given to further explore
the feasibility and practical operation of this new development
and manufacturing approach for chemical products. In this context,
the project ‘Fast Flexible Future Factory’ (F3 Factory), which
is granted by the European Union, can be considered as a lighthouse
project which enables us to successfully manage the step
towards a new decade for highly efficient and highly flexible
(bio-)chemical production technology.
Today the standard of biotechnological production is mainly characterized
by ‘large size’ fermentation vessels and non-removable,
fixed installed stainless steel pipings. These plants are operated
only by a few Pharma-/ Biotec companies worldwide, due
to their high investment costs and their requirements for stringent
process control systems. However, this current technology
suffers from limited flexibility (mono purpose plants) as well as
from high operational costs, which is rooted in the high effort
for cleaning and operating these plants. A promising solution to
overcome these shortcomings can be seen in the industrial use of
modular and disposable medium-scale units (up to some 1.000
l volume) which then can be combined to a complete up- and
downstream process train and hence to an integral fermentation
process. Using the principles of ‘Closed Processing’ could even
allow the production of biopharmaceuticals in former lab facilities,
since the primary product conditions would then be leveraged
to a GMP-compliant environment. Bayer Technology Services,
together with Bayer Schering Pharma is striving to develop
these new manufacturing technologies to make them available
for single unit operations up to complete process chains. The Bayshake
system which was co-developed by Bayer Technology Services
and Sartorius Stedim Biotech allows to increase production
flexibility and production capacity while production costs can be
significantly reduced simultaneously.
Bayshake ® Demo System with Disposable Bag: The Bayshake system which was co-developed by Bayer Technology
Services and Sartorius Stedim Biotech allows to increase production flexibility and production capacity while production
costs can be significantly reduced simultaneously

28
The Life Science Screening Package Berlin-Brandenburg is tailored
to the needs of the biotech sector. This program supports companies
looking for cooperation partners, networks, service providers
and research institutions. All segments of the health industry
are present in the region. The high concentration of international
excellence facilitates interdisciplinary exchange and makes new
landmark developments easier to achieve – this is what makes
Berlin-Brandenburg so interesting and attractive for the life sciences.
At the same time, however, the sheer number of players
can make it difficult to find the right partner. Our staff and the
colleagues at BioTOP have been in direct contact with virtually all
companies and scientific institutions in the region for many years
and can therefore provide immediate access to the right contacts.
The other services of Berlin Partner include the Business Welcome,
Business Financing, Business Locating and Business Recruiting
Package. They help our clients test Berlin as a location, procure
support and funding and identify suitable commercial real estate
or professional staff. The Business Location Center (BLC) presents
all relevant economic data and a 3D model online and in
its showroom. Its comprehensive information service covers sector
data, regional information, area maps, geographic data, the
available funding programs, a commercial real estate database as
well as labor market and infrastructure data. At the start of this
year, a new service was launched for companies in the region
offering support in all aspects of corporate expansion and strategy
in cooperation with the Berlin Senate Administration for Economic
Development, Technology and Women, the twelve Berlin
precincts and other service partners.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Excellent Corporate Locating and Project
Development Services
Berlin-Brandenburg is Germany’s leading life science center and one of Europe’s main
health industry locations. Due to its high concentration of science and research establishments,
the region offers outstanding potentials for technological development and cooperation.
The joint Life Science Team of the economic promotion agency Berlin Partner and
the Brandenburg Economic Development Board (ZAB) supports the life science industry
with a full range of services, including marketing activities at national and international
exhibitions.
Carolin Clement
Head of Business Unit Life Sciences
Berlin Partner GmbH
Dr. Ute Hartmann
Head of Business Unit Life Sciences
Brandenburg Economic Development Board
The performance range of the one-stop agency ZAB includes corporate
strategy, innovation, technology and foreign trade services,
support for technology transfer and for the establishment of corporate
networks. Under its „Big Directive“, the state of Brandenburg
now also sponsors innovative cooperation projects between
research institutes and companies. Here, landmark initiatives
include the Tele-Diagnostics cooperation project (with funding
of app €10 million) and TERA-Sens (€15 million). The participating
partners include the Fraunhofer Institute for Biomedical
Engineering, the University of Potsdam, the Leibniz Institute for
Innovative Microelectronics (IHP) and the companies B.R.A.H.M.S
AG (Thermo Fisher Scientific), MEYTEC GmbH and LIMETEC Biotechnologies
GmbH. In 2009, the Life Science Team successfully supported
64 high-end innovation projects with a total funding volume
of €89 million, creating some 300 new jobs.
The Life Science Team supported expansion projects and provided
locating services to 35 companies in 2009, including Pfizer
Deutschland GmbH which is transferring further divisions to Berlin
with some 200 new jobs, Deutsche Gesellschaft für Humanplasma
mbH, Japan Stent Technology Europe GmbH and the Iranian
biotechnology firm UGA Biopharma GmbH.

Good News
for your company
1 We interconnect science and business.
UP Transfer GmbH provides direct access to science and R & D resources of the University
of Potsdam for your company. We realize know-how and technology transfer from the
university into practice. Take advantage of our contacts and networks and profit from
our efficient project management to take your business to the next level. Please contact
us for further information: info@up-transfer.de
www.up-transfer.de

30
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The BioCampus Network Berlin-Brandenburg
Berlin-Brandenburg boasts six biotechnology parks, which offer optimal space for the
specific requirements of every company. This geographic concentration of specific biotech
parks is unique in Germany and probably in all of Europe. The parks differ in their offers
and strategic focus and provide ideal conditions for newcomers. More than half of the 195
companies are currently utilizing the infrastructure of a publicly or privately managed park.
In addition, the young companies benefit from the closeness to science and the perma-
nent contact and exchange.
Campus Berlin-Buch
Interaction of Research, Clinics and Companies
Berlin-Buch is the location of one of the largest biotechnology
parks in Germany, with 26.000 square meters of scalable lab and
office space for start-ups and maturing companies. Situated to
the northeast of the city, the Berlin-Buch Campus is currently
home to 49 companies, 35 of which are biotech companies; the
rest provides support services.
Beside the BiotechPark the Max Delbrück Center for Molecular
Medicine, the Leibniz Institute for Molecular Pharmacology as
well as clinical groups from the Charité University Hospital within
the Experimental and Clinical Research Center are part of the
Campus community. The Campus gives access to high-end technology
platforms, state of the art infrastructure, interdisciplinary
communication, projects and expertise in a wide range of items,
especially in translational research.
The BiotechPark at the Campus Berlin-Buch offers:
p Immediately available lab and office space
p Excellent research and clinical expertise on-site
p Training programs for personnel on spot
p An international community of like-minded people
p Interdisciplinary networks and platforms
The BiotechPark including the Innovation and Incubation Center
is managed by BBB Management GmbH Campus Berlin-Buch. Acting
as s full-service company BBB’s main tasks are the settlement,
accompanying and support of Biotech businesses.
Biotechnology Park Luckenwalde
Space for Expansion
Located just 25 miles from the new Berlin-Brandenburg International
Airport (BBI) in the rural district of Teltow- Flaeming, the
Biotechnology Park Luckenwalde is one of the most modern facilities
of its kind in Germany. It is home to 38 companies with 500
employees from Germany, USA, UK, Korea, India, Italy and Russia.
Companies in the park focus on the development and production
of pharmaceuticals, recombinant proteins and diagnostic kits,
biological/chemical substances for biotech and pharmaceutical
applications, as well as fine chemicals. There are also suppliers
of medical technology, analytical services, and a Biotech Education
Centre. Technical Equipment comprises completely furnished
S2 labora tories (safety workbench, autoclave, dishwasher,
deionized water, water purification system, central media supply
(compressed air, N 2 , Co 2 , O 2 , H 2 ), storage and cool rooms, pharmaceutical
clean rooms category (B/C), 400 MHz NMR spectrometer,
meeting rooms, conference hall (300 seats), library, restaurant
with catering service. The entire central technique meets GMP/ISO
9001 specifications.
The park management offers comprehensive, individual services
and advice during the settlement and development of firms,
including support for the implementation of quality management
systems and GMP certification. Currently the park offers 15.000
sq.m. labs and office space, and additional 100.000 sq.m.
industrial property ready for expansion.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Berlin Adlershof
The “City of Science, Technology and Media”
Berlin Adlershof is one of the most successful high-tech locations
in Germany with focus on photonics and optical technologies,
material and microsystems technology, information and media
technology, as well as biological, environmental and energy technology.
There are currently 25 biotech companies in Adlershof occupying
18,200 sq.m of lab and office space. The environmental, biological
and energy technology companies focus on:
p Analysis
Tracing substances in foodstuffs and groundwater, cosmetics,
waste; Quality assurance, Identification of pollutants
p Biotechnology
Research development and marketing or manu facture of base
materials for biotechnology and chemical processes, of biochips
and biochip-based biomedical procedures, of technical
enzyme preparations
p Environmental technology
Remediation work based on innovative microbiological processes
for degradation of pollutants or production of specific
microbial anacultures; Research in the field of supercritical
media and high-pressure technology; High-sensitivity detection
systems for biotechnology and gene tic engineering; Laser
technology
p Pharmacy, Medicine and Medical Technology
Equipment engineering and measurement technology;
Research for medical chemistry
Technical Equipment comprises laboratories with a basic equipment:
security-lockers, laboratory basins, work benches, vacuum
supply, preliminary setup for supply of pure gases and compressed
air, reconfiguration for further media and gases, central
cooling, preliminary setup for cold water supply in rental areas,
refitting of heat exchanger by the tenant possible.
BIOTECh CAMPUS POTSDAM
Research on the Waterfront
Just a few minutes away from Potsdam’s central railway station
in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located
on the Hermannswerder peninsula in the river Havel. It is owned
and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned
subsidiary of the Investment Bank of the State of Brandenburg.
The biotechnology centre is housed in four buildings dating
from around 1900 and one modern complex and offers a total
of 11,400 square meters of laboratory, office, greenhouse and
storage space. With such a large facility at its disposal, it offers
biotechnology companies an ideal environment for successful
operations. All labs are approved as S1 laboratories and meet the
building requirements for approval as S2 labs.
The Hermannswerder site also includes an S3 laboratory as a
special resource. The beautiful, park-like setting of the peninsula
offers an excellent environment for research activities. The
island hotel and a conference centre are located directly next to
the campus. The site also includes a self-service restaurant and
small island shop.
The philosophy of BIOTECH CAMPUS POTSDAM was, and still is, to
create the freedom for research and innovation in the high-tech
sector of biotechnology. Reputable firms from the industry can
indeed be found here. The work carried out by resident companies
is multi-faceted, ranging from green biotechnology, the
development of vaccines, the development of pharmacologically
active substances based on plant materials, the development
and production of PCR tests for food testing and preclinical contract
research right through to medical technology. A total of 200
employees work on the site.
31

32
berlinbiotechpark
In the very heart of Berlin
berlinbiotechpark is located on a 86,000 m² site in the very heart
of Berlin, currently offering a total of approx. 57,000 m² of office,
laboratory and production space, with a building potential for
another 45,000 m² of rental area.
The site, which is home to 32 Biotech/Pharma/Service Companies
is supplied with a complete range of media for laboratory and
production purposes, with production steam with possibility to
upgrade to HP steam, power supply, compressed-air, nitrogen
and other inert gases, cooling water, DI-water, with possibility
to upgrade to aqua purificata and water for injection, all being
provided at favorable rates. The infrastructure includes a canteen
and conference facilities as well as works security and waste disposal
services. It is rounded off by production-related services
such as plant engineers and laboratory technicians, industrial
safety engineers, a medical service as well as best-buy services
and communication services.
Offering flexible growth potential, production-orientated media
equipment and comprehensive industrial-specific services and
infrastructure, berlinbiotechpark is particularly attractive for
growing internationally orientated technology companies. Furthermore,
it offers a permanent base in Berlin for developing
companies that have outgrown the size allowed by their limited
start-up funding. The inner-city location and the excellent public
transport guarantee short ways to all scientific institutions and
hospitals of the city.
BIOTECH CAMPUS
POTSDAM GmbH
Science Park Potsdam-Golm
Connecting Excellence
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Science Park Potsdam-Golm combines cutting-edge international
research and the training of young scientists in a high-powered
location in the immediate vicinity of the German capital Berlin.
Alongside the Faculty of Science and the Human Sciences Faculty
of the University of Potsdam, three Institutes of the Max Planck
and two of the Fraunhofer Society as well as an innovation center
with currently 18 companies operate in Brandenburg’s largest
science park.
More than 2500 people work at Potsdam-Golm and more than
7500 students are pursuing their academic qualifications here.
The pleasant and very family-friendly working environment on
the edge of a nature conservation area, the high quality of life
in and around Potsdam and continuous growth make Potsdam-
Golm a highly attractive location. Professional site management
is extending the park infrastructure and fosters the integration of
the capabilities and interests of all institutions, associations and
companies that operate at Science Park Potsdam-Golm.
The GO:IN Innovation Center offers young technology-based companies
and entrepreneurs a range of office and laboratory spaces
along with extensive services and optimal support for a successful
market launch. Close proximity to the other players at Potsdam-
Golm and the intensive networking of the different institutions
and companies here offer perfect conditions for the development
and exploitation of synergies.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The BioTechnology Center Hennigsdorf
On the northern perimeter of Berlin, a number of biotech and
medtech companies have been established at the BiotechnologieZentrum
Hennigsdorf around the diagnostics company
B.R.A.H.M.S. As a traditional industrial site with very good transport
connections, the 27,000-strong town has evolved into an
important Brandenburg location for technology fi rms.
The BiotechnologieZentrum Hennigsdorf was set up in 2001. It
offers full service for small and mid-sized biotech companies.
Infrastructure and services include:
p Laboratories up to security level S2, isotope labs, clean rooms
(small area)
p Production and storage areas
p Advice on start-up, funding and subsidy issues
p Conference and meeting rooms, conference organisation,
event management
p Security guards, alarm
p Technicians, building surveillance
Apart from these locations with strong focus on biotechnology
which form the BioCampus Network there are many other technology
parks that offer a good technical infrastructure for life science
companies. Among them is the Innovationspark Wuhlheide
which is in close proximity to the Adlershof technology park.
Addresses
Campus Berlin-Buch
Robert-Rössle-Straße 10 · 13125 Berlin
Phone +49 30 94892511 · Fax +49 30 94893812
info@bbb-berlin.de · www.bbb-berlin.de
Contact: Dr. Andreas Mätzold · Executive Manager
Dr. Ulrich Scheller · Executive Manager
Biotechnologiepark Luckenwalde
c/o SWFG mbH
Im Biotechnologiepark, TGZ I · 14943 Luckenwalde
Phone +49 3371 681100 · Fax +49 3371 681105
bio-luck@swfg.de · www.bio-luck.de
Contact: Dipl.-Ing. Christoph Weber · Director
Adlershof Zentren für Biotechnologie und Umwelt
WISTA-MANAGEMENT GMBH
Rudower Chaussee 17 · 12489 Berlin
Phone +49 30 63922221 · Fax +49 30 63922212
terytze@wista.de · www.adlershof.de
Contact: Heidrun Terytze · Head of Center for Biotechnology
and Environment
BIOTECh CAMPUS POTSDAM
Steinstraße 104-106 · 14480 Potsdam
Phone +49 331 6601169 · Fax +49 331 6601201
info@biotechcampus.de · www.biotechcampus.de
Contact: Marco Fredersdorf · Executive Manager
berlinbiotechpark
Tegeler Weg 33 · Max-Dohrn-Straße 8-10 · 10589 Berlin
Phone +49 30 20364205 · Fax +49 30 20364190
info@berlinbiotechpark.de · www.berlinbiotechpark.de
Contact: Ingo Schneemann
Standortmanagement Golm gGmbh
GO:IN Golm Innovationszentrum Gmbh
Am Mühlenberg 11 · 14476 Potsdam-Golm
Phone +49 331 237351130
www.wissenschaftspark-potsdam.de · www.goin-potsdam.de
Contact: Friedrich W. Winskowski · Managing Director
Biotechnologiezentrum hennigsdorf/B.R.A.h.M.S Biotech Gmbh
Neuendorfstraße 24b · 16761 Hennigsdorf
Phone +49 3302 883250 · Fax +49 3302 883666
s.linert@brahms-biotech.de
Contact: Steffi Liniert
Innovationspark Wuhlheide
Köpenickerstraße 325 · 12555 Berlin
Phone +49 30 65762431 · Fax +49 30 65762799
koch@ipw-berlin.de · www.ipw-berlin.de
Contact: Henry Koch | Park Management
33

34
Biotechnology in Schools
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The biotech industry is growing and needs fresh talents. Young people often take the deci-
sion to embark on a career in this field while still at school. This is why special programs
aimed at promoting excitement about biotechnology among school students have been
established in Berlin-Brandenburg.
Everybody involved in biotechnology in Berlin-Brandenburg
knows BIONNALE, the annual reception at which entrepreneurs,
scientists, financers and others in the industry meet to exchange
their experiences. The themes discussed here are scientific progress,
innovations, the economic environment – and often the
recruitment of junior talents too. After all, the industry is growing
and needs well-trained professionals. However, potential young
recruits are not present at BIONNALE. In fact, they are not invited
because that would simply not be suitable at this event.
Dr. Norbert Gerbsch
Honorary Chairman
Biotechnologieverbund Berlin-Brandenburg
So, there should really be a separate BIONNALE for school students,
an event that introduces them to the industry and the careers it
offers, thought Beate Mitzlaff last year, who is reponsible both for
education and events at BioTOP. She decided to develop a concept
for the SchülerBIONNALE for school students and went on to
implement it too. Under the motto „Experience and Discover the
Life Sciences“, more than 600 secondary and sixth form pupils
from Berlin and Brandenburg came to Langenbeck Virchow House
in Berlin to find out what is happening in the world of biotechnology.
The program included a short lecture on stem cells, an
introduction to the different careers in the field, a crash course
for successful applications (Barefoot or Patent Leather?) as well as
experiments and discussions with representatives from companies
and educational institutions. Since not everything there is to
know could be communicated and understood in just two hours,
pupils received extensive material on a USB stick, and the teachers,
too, were supplied with documents and posters to continue
presenting the subject in class.
Call a Scientist
Students and teachers who developed an interest in biotechnology
at the SchülerBIONNALE find it easy to build on that experience.
They can request a bioscientist to give a talk at their school
from the initiative „Call a Scientist“ organized by the Berlin-
Scientists for Schools
» Natural science education in schools and attracting young
people to careers in science and research is vital for the
future of Germany and our region Berlin-Brandenburg as an
internationally competitive science and technology location.
It is impossible to understand the world without science, and
the biosciences are playing an increasingly important role in
many areas of our global economy. For young people, the
biosciences can therefore provide an opportunity to embark
on exciting and promising careers. This is why our initiative
„Call a Scientist“ sends science experts into schools to present
their areas of expertise to pupils.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Brandenburg Biotechnology Association. On its website www.
call-a-scientist.org, this service, which was launched in 2006,
offers users the choice between more than 100 speakers with
different specialties. And demand is growing continuously. The
Beate Mitzlaff
Event Manager
BioTOP Berlin-Brandenburg
Berlin-Brandenburg also offers outstanding international postgraduate programs in the life sciences.
p Berlin-Brandenburg School for Regenerative Therapies
p Berlin Institute for Medical Systems Biology PhD Program
p Berlin International Graduate Schools of Natural Science and
Engineering
p Berlin School of Mind and Brain
p Bernstein Center for Computational Neuroscience
p Dahlem Research School Biomedical Sciences
p Dahlem Research School Molecular Plant Science
p Dahlem Research School Molecular Science
p DFG Research Training Group Cellular Mechanisms of Learning
and Memory Consolidation in the Hippocampal Formation
p DFG Research Training Group Genetic and Immunologic
Determinants of Pathogen-Host-Interactions
p DFG Research Training Group Hormonal Regulation of Energy
Metabolism, Body Weight and Growth
p DFG Research Training Group Sex- and Gender-Specific
Mechanisms in Myocardial Hypertrophy
p DFG Research Training Group The Impact of Inflammation on
Nervous System Function
initiative has already arranged 114 talks to some 4800 students
in the region to date. In addition, school student laboratories
for experiments have also been well established for many years
(www.genau-bb.de).
Learning About Careers in the Life Sciences
» At SchülerBIONNALE, school students can experience and explore the life sciences. We provide
them with personal contact to students, technical assistants, scientists and companies
to find out more about careers and working life in this sector. Information about professions in
the life sciences must be improved to give pupils a realistic understanding of what to expect in
the industry. We want to support them in developing their talents and provide them with initial
insight into the role of the biosciences in everyday life.
p Helmholtz International Research School ‘Molecular
Neurobiology’
p International Max Planck Research School on Biomimetic
Systems
p International Max Planck Research School Primary
Metabolism and Plant Growth
p International Max Planck Research School for Computational
Biology and Scientific Computing
p International Max Planck Research School for Infectious
Diseases and Immunology
p International Research Training Group (IRTG) Genomics and
Systems Biology of Molecular Networks
p International Research Training Group for Myology
p International PhD Programme Molecular Cell Biology
p International Graduate Program Medical Neurosciences
p Leibniz Graduate School of Molecular Biophysics
p Postgraduate International Process Engineering School (PIPES)
p TransCard Research School
35

Life sciences companies are in safe hands with UHY.
UHY Deutschland AG is a joint venture of long established
medium-sized auditing and consulting firms with a total of
150 employees and partners.
As a member of UHY International, a global association
of independent accounting and consulting firms with
about 7,600 employees we can provide audit, accounting,
tax and consulting services in over 200 business centres
across the globe.
Anhaltinerstraße 22
14163 Berlin
Phone +49 30 801971 11
Fax +49 30 801971 20
info@consultech.de
www.consultech.de
Contact
Dr. Ulla Peters or Reinhold Lauer
UHY Deutschland AG Wirtschaftsprüfungsgesellschaft / Zimmerstraße 23 / D-10969 Berlin
Phone +49 30 226593-0 / Fax +49 30 22679050 / www.uhy-deutschland.de / www.uhy.com
Grants for R&D Projects in Life Sciences
Berlin / Bremen / Cologne / Hamburg / Munich
Since 1992, ConsulTech GmbH supports companies and research
institutions in the acquisition of funding for their R&D projects by
public grants (German, EU and US).
We have specialized on projects in the area of biotechnology,
medical technology, pharmaceutical development and
environmental technology.
p We identify grants that facilitate your innovation.
p We conceive, compose and chaperone your R&D projects
by planning, writing, filing and implementing proposals.
p We find and assemble partners from industry and science
to build research consortia that fit.
You focus on the scientific success - we take care of the
administration and project management.
UHY Deutschland AG has extensive experience in financial
and consulting services for life sciences companies for
many years. We offer the following services:
p Audits of financial and consolidated statements under
the German Commercial Code (HGB) and IFRS
p Accounting & Reporting
p Due diligence (financial and tax) and business valuations
p Consulting services on IPOs
p Business Advisory
p Mergers & Acquisitions (M&A)
p German and international taxation

38
Biotech Networks
BioHyTec Network for Biohybrid Technologies
BioResponse
Center for Molecular Diagnostics and Bioanalytics (ZMDB)
DiagnostikNet-BB
GABI – Genome Analysis in the
Plant Biological System
NetDDD Network for Drug Discovery &
Development Berlin-Brandenburg
Network Glycobiotechology Berlin-Brandenburg
Nutrigenomics Network Berlin-Brandenburg
Regenerative Medicines Initiative
Berlin-Brandenburg
RiNA Network for RNA Technologies
Ultrastructure Network
Scientific Institutions
Berlin-Brandenburg Center for
Regenerative Therapies
Berlin Institute of Technology
Brandenburg University of Technology
Charité Universitätsmedizin Berlin
Fraunhofer Institute for Applied Polymer Research
Fraunhofer Institute for Biomedical Engineering (IBMT)
Freie Universität Berlin
German Heart Instiute Berlin
German Institute of Human Nutrition (DIfE)
German Rheumatism Research Center (DRFZ)
Humboldt-Universität zu Berlin
Institute of Polymer Research of the
GKSS Research Centre
Lausitz University of Applied Sciences
Leibniz-Institute for Agricultural Engineering
Potsdam-Bornim (ATB)
Leibniz-Institut für Molekulare Pharmakologie (FMP)
Leibniz-Zentrum für Agrarlandschaftsforschung
(ZALF) e. V.
Max Delbrück Center for Molecular Medicine (MDC)
Berlin-Buch
Max-Planck-Institute for Colloids and Interfaces
Max Planck Institute for Infection Biology
Max Planck Institute for Molecular Genetics
Max Planck Institute of Molecular Plant Physiology
Robert Koch Institute
University of Applied Sciences Berlin
University of Applied Sciences Wildau
University of Potsdam
J Bioparks
J Scientific
Institutions
J Companies
J Networks
BIOTECH CAMPUS
POTSDAM GmbH
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Netzwerk Glykobiotechnologie Berlin-Brandenburg

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
IFHI 39

Wir bei BIOCOM sind ständig
für Sie auf dem Quivive!
Seit der Besetzung Preußens durch Napoleon gibt es in Deutschland die Redewendung
„auf dem Quivive sein“, was so viel bedeutet wie auf der Hut sein, aufpassen,
aufmerksam oder auch besonders gut informiert sein. Die Mitarbeiter der BIOCOM AG
und ihrer Tochtergesellschaften haben Bioökonomie und Life Sciences europaweit für
Sie ständig im Blick. Davon profitieren Sie als Leser unserer Zeitschriften und Bücher,
als Gäste unserer Tagungen und Kongresse, als Besucher vieler verschiedener Onlineplattformen
wie etwa biotechnologie.de, als Kunden unserer erfahrenen Beraterteams,
als Nutzer unserer Studien und Umfragen, als Zuschauer von Videomagazinen wie
biotechnologie.tv, als Auftraggeber vielfältigster Kommunikationsdienstleistungen
rund um die Biotechnologie.
In den vergangenen 24 Jahren wurden wir so zum führenden Fachinformationsunter-
nehmen für Bioökonomie und Life Sciences in Europa. Was können wir für Sie tun?
BIOCOM AG | Stralsunder Str. 58–59 | 13355 Berlin | Germany
www.biocom.de | service@biocom.de
Tel. +49 (0)30/264921-0 | Fax +49 (0)30/264921-11

Profiles
rofiles
metanomics GmbH + metanomics Health GmbH 42
Epigenomics AG 43
caprotec bioanalytics GmbH 43
Silence Therapeutics AG 44
ORGANOBALANCE GmbH 45
BST 45
B·R·A·H·M·S AG 46
LGC Genomics 47
PAREXEL International GmbH 47
RiNA GmbH 48
BLS Preclinical Services 49
analyze & realize ag 49
Analytisches Zentrum Biopharm GmbH Berlin (AZB) 50
Biochrom AG 51
ProteaImmun GmbH 51
provitro GmbH 52
NOXXON Pharma AG 53
Glycotope GmbH 53
Evestra GmbH 54
BIOTECON Diagnostics GmbH 54

42
metanomics GmbH + metanomics Health GmbH
Metabolite Profiling for plant biotechnology,
drug development and diagnostics
Metabolite profiling – or metabolomics
- is the parallel measurement of
several hundred up to thousands of
known and unknown endogeneous and
xenobiotic metabolites in a given sample
from plants, microbes, animals or
humans. This unbiased approach allows
the observation of whole systems and
is being employed in a wide range of
applications spanning the entire spectrum
of biology. Whilst being highly
complex and representing a large range
of different chemistries, the metabolome
comprises molecules which are
indicative of the genetic or physiological
status of an organism. The metabolome
reflects the entirety of internal or external
influences on an organism or tissue
– including environment, behaviour,
chemical treatment and disease. Profiling
metabolites is not a new concept –
metabolites have been used as valuable
indices of phenotypes for many decades
– but the improved analytical and
informatics technologies exponentially
increased the power of the approach in
the last years.
metanomics Gmbh
Founded in 1998 metanomics has
established the worldwide leading
Metabolite Profiling platform based on
mass spectrometry technologies and
informatics. Being part of the international
BASF Plant Science research platform
metanomics has analyzed more
than 2 million metabolite profiles over
the last years looking at more than
55,000 gene functions. This led to the
worldwide largest gene-function database
for plant biotechnology. With this
multi-year experience and knowledge
metanomics has advanced metabolite
profiling at an unparalleled scale,
metabolite range and quality of results.
metanomics supports highly successfully
a broad range of applications. With >75
mass spectrometry instruments (GC-MS,
LC-MS/MS and more) metanomics has
the worldwide leading metabolite profiling
platform.
metanomics health Gmbh
metanomics Health, founded in 2003,
uses the technology platform and expertise
of metanomics for the identification
and interpretation of metabolite biomarkers
for drug efficacy, toxicity, disease
or physiological status. The metabolites
measured by metanomics Health
include a wide range of known substances
like amino acids, organic acids,
fatty acids, lipids, sugars, hormones etc.
and a multitude of known-unknown
metabolites whose structure can be
identified if they appear as important
biomarker candidates. Metabolite Profiling
can be applied for a wide range
of sample types like plasma, urine, CSF,
tissues and many more. metanomics
Health applies statistics to identify specific
changes of single or complex combinations
of metabolites which correlate
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
with disease, drug treatment or other
influences.
metanomics Health cooperates with
companies from the diagnostics, pharma
and life science industry to support
their product development and further
conducts own and collaborative projects
with leading clinics and academic institutes
to discover, develop and validate
disease biomarkers in a range of indications.
Address
metanomics GmbH
Tegeler Weg 33
10589 Berlin · Germany
company.info@metanomics.de
www.metanomics.de
Phone +49 30 34807100
Contact
Dr. Arno Krotzky
Managing Director
company.info@metanomics.de
Phone +49 30 34807 101
Fax +49 30 34807 301
Address
metanomics Health GmbH
Tegeler Weg 33
10589 Berlin · Germany
company.info@metanomics-health.de
www.metanomics-health.de
Phone +49 30 34807400
Contact
Dr. Tim Boelke
Managing Director
company.info@metanomics-health.de
Phone +49 30 34807 400
Fax +49 30 34807 401

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 43
Epigenomics AG
Epigenomics is a molecular diagnostics
company developing products for cancer
based on DNA methylation technology
and biomarkers.
In cooperation with industry partners,
the company develops diagnostic tests
for the early detection, diagnosis, prognosis
and diagnostic follow-up of cancer,
products that address an attractive segment
of the molecular diagnostics market.
Based on easily obtainable patient
samples that do not require invasive pro-
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH has developed
a ground-breaking, proprietary
tech nology to reduce the complexity of
protein mixtures and samples in a targeted
and directed manner.
Founded in 2006 by scientist and entrepreneur
Prof. Dr. Hubert Köster, founder of
Sequenom Inc. and Biosyntec, caprotec
raised approx. 9 million $ in 2007 and
is operational in Berlin Adlershof since
the beginning of 2008 and currently has
24 employees.
caprotec’s Capture Compound Mass Spec -
trometry (CCMS) Technology is based on
multifunctional small molecules that are
used to target, capture, and isolate proteins
based on their functionality. The
company is commercializing the CCMS
technology as kits for research applications
and in the form of collaborations
for drug development.
cedures beyond the current clinical routine,
the tests are aimed at finding cancer
at an early stage before symptoms
occur and at providing additional diagnostic
information that may help to treat
the cancer with better success. The companys
first CE-marked IVD blood test (Epi
proColon) for colorectal cancer early
detection was introduced in late 2009
and is currently being made available in
more and more countries across Europe.
In the pipeline are tests for improved
diagnosis and prognosis assessment in
caproKit for the characterization of
staurosporine binding protein kinases
In collaborations for drug development
caprotec is using small molecule drugs
or drug candidates to establish a profile
of proteins that interact with the specific
small molecule. The profile can be used
to elucidate the mode of action of drugs
and drug candidates and also to discover
off-target proteins that are responsible
for unwanted side effects, e.g. liver toxicity.
lung and prostate cancer indications.
Partners in the health care industry and
the biomedical research community can
access Epigenomics’ portfolio of proprietary
DNA methylation technologies and
biomarkers protected by more than 150
patent families through research products,
biomarker services, IVD development collaborations,
and licensing. The company
is headquartered in Berlin, Germany, and
has a wholly owned subsidiary in Seattle,
WA, USA. For more information, please
visit Epigenomics’ website.
Address
Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin · Germany
Phone +49 30 243450
Fax +49 30 24345555
contact@epigenomics.com
www.epigenomics.com
Address
caprotec bioanalytics GmbH
Volmerstraße 5
12489 Berlin · Germany
Contact
Dr. Christian Jurinke
Director, Product Management
Phone +49 30 63 92 3992
christian.jurinke@caprotec.com
www.protec.com

44
Silence Therapeutics AG
SILENCE Therapeutics AG is the leading
RNAi therapeutics company in Europe.
The Company has developed novel, proprietary
short interfering RNA (siRNA)
molecules called AtuRNAi and a proprietary
systemic delivery system for siRNA
called AtuPlex. In June 2009 SILENCE
started its first Phase I Clinical Study for
Atu027.
Strong IP Position
SILENCE’s strong IP position is based on
patents issued in the US, Europe and
other territories.
Validating Pharma Partnerships
SILENCE has established validating
partnerships with AstraZeneca ($15m
upfront payment & equity, $400m milestone
payments), Pfizer/Quark ($95m
milestone payments) & Dainippon Sumitomo
Pharma (delivery collaboration).
4 Clinical AtuRNAi Programs
Out of 8 clinical siRNA programs worldwide
as of April 2010 there are 4 clinical
programs (one in phase II and three
in phase I) with SILENCE’s AtuRNAi molecules.
These are SILENCE’s internal lead
program Atu027 and three clinical study
programs conducted by SILENCE’s partners
Pfizer and Quark. This underlines
SILENCE’s leadership in the field of siRNA
therapeutics.
Overview of AtuRNAi Programs
Products Indications Partners Research Preclinical Clinical Milestones 2010
RTP801i Macular Edema (AMD/DR) Pfizer/Quark Continue phase II clinical study
AKli-5 Acute Kidney Injury Quark Continue phase I clinical study
QPI-1002 Delayed Graft Function Quark Continue phase I clinical study
Atu027 Solid Tumors Internal Continue phase I clinical study
Atu134 Acute Lung Injury Internal Progress pre-clinical studies
AHLi-11 Acute Hearing Loss Quark Progress pre-clinical studies
Atu111 Solid Tumors Internal Progress pre-clinical studies
Atu150 Solid Tumors Internal Progress pre-clinical studies
5 Programs Mainly Respiratory Astra Zeneca Advance research
Internal Lead Program
SILENCE’s internal lead program Atu027
is currently in a Phase I clinical study
recruiting patients with advanced gastro-intestinal,
lung and other solid
cancer. The Phase I study started in June
2009.
Recent Corporate Highlights
p March 30, 2010 Expansion of the siR-
NA Delivery Collaboration with Dainippon
Sumitomo Pharma started in
August 2009 in order to examine the
delivery to additional disease targets.
p February 8, 2010 United States Patent
and Trademark Office issues a
Notice of Allowance to SILENCE for
its RNAi patent application covering
PKN-3, a therapeutic oncology target.
PKN-3 is believed to play an important
role in the growth of cancer cells
and metastasis formation. The claims
cover the siRNA molecule in SILENCE’s
lead chemical compound Atu027,
which targets PKN-3 for the treatment
of advanced solid tumors.
p January 5, 2010 Merger with US
based Intradigm Corporation - The
enlarged company now possesses
multiple RNAi discovery, development
and delivery technologies, an
advancing internal and partnered
product pipeline and a broad portfolio
of intellectual property.
p August 27, 2009 SILENCE starts siRNA
delivery collaboration with Japan
based Dainippon Sumitomo Pharma.
The collaboration includes SILENCE’s
AtuPLEX delivery technology.
p June 3, 2009 SILENCE receives approval
from German regulatory authority
BfArM to initiate Phase I clinical trials
on Atu027 for treatment of patients
with advanced solid cancer.
p January 8, 2009 Quark Pharmaceuticals
announces further Phase I/II
clinical trials for QPI-1002 (prevention
of delayed graft function), a
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
drug based on SILENCE’s proprietary
chemistry AtuRNAi.
p January 7, 2009 European Patent
Office (EPO) grants patent to SILENCE
that covers the company’s lead
product candidate Atu027. The patent
covers the use of protein Kinase
N3 (PKN-3) gene for drug-screening,
diagnostic and therapeutic purposes.
SILENCE Therapeutics AG, Berlin, is listed
through its holding company SILENCE
Therapeutics plc, London, at the Alternative
Investments Market (AIM) of the
London Stock Exchange.
Address
Silence Therapeutics AG
Robert-Rössle-Straße 10
13125 Berlin · Germany
Contact
Thomas Christély
Chief Executive Officer
Dr. Klaus Giese
Chief Scientific Officer
Yme Alkema
Director Business Development
Phone +49 30 9489 2800
Fax +49 30 9489 2801
www.silence-therapeutics.de
info@silence-therapeutics.com

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 45
ORGANOBALANCE GmbH
In harmony with Nature
ORGANOBALANCE GmbH is a company
specializing in microbial strain development
and microbiological screening.
ORGANOBALANCE taps into the potential
of beneficial microorganisms, known as
specific probiotic cultures, to compensate
imbalances in the microflora on a
natural basis and restore the microbial
equilibrium.
BST
The new generation of glucose measurement
– BST’s contribution for optimal
medical diagnostics and therapy!
BST’s history dates back to 1975 when a
biosensor research group started at the
Berlin Academy of Sciences. Already in
1982 the first European glucose analyzer
based on a glucose biosensor could be
launched. Today, BST is the market leader
in multi-way biosensors in Europe
In close cooperation with leading industry
partners ORGANOBALANCE develops
new biological products in the areas of
nutrition, cosmetics and preventive health
care. In its development activities, the
company draws on its own collection of
microorganism strains suitable for food
applications and its OASSYS ® screening
systems.
Using innovative screening technologies
and individually configured test designs,
those strains of microorganisms are filtered
that match application-specific
criteria. For suitable strains, fermentation
and downstream processes are developed
in a pilot scale production facility.
In a long-term partnership with leading
international companies ORGANOBALANCE
developed marketable strains of probiotic
cultures that combat tooth decay, body
odour and skin irritation on a natural
basis.
and an international operating company.
Our competence is the development,
production and distribution of
multi-way biosensors, instruments
based on these multi-way biosensors
and all related consumables. Based
on the competence in development
and production of multi-way biosensors
BST is working continuously for the
improvement of quality in diagnostics of
metabolism in clinical laboratories and
the POCT area. Our latest products, the
instruments GLUKOMETER PRO and LAC PRO ,
bring our lab quality from the clinical
laboratory into the POCT area causing
measuring results of lab quality at
the bedside. BST’s latest development
for the application in laboratories is the
LABTREND – a flexible and economical
analyzer for the determination of glucose
or lactate concentrations. For more
information, please visit our website at
www.bst-biosensor.de.
ORGANOBALANCE has a comprehen sive
knowledge and experience in the field
of industrial biotechnology and develops
strains by means of metabolic engineering.
Address
ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin · Germany
Contact
Dr. Christine Lang · CEO
Phone +49 30 46307200
Fax +49 30 46307210
info@organobalance.com
www.organobalance.com
Address
BST Bio Sensor Technology GmbH
Buchholzer Str. 55-61
13156 Berlin · Germany
Contact
Dr. Dorothea Zahn
Phone +49 30 76767310
Fax +49 30 767673128
info@bst-biosensor.de
www.bst-biosensor.de

46
B·R·A·H·M·S AG
B·R·A·H·M·S is a global biotechnology
company that develops and markets its
patent-protected diagnostic biomarkers
worldwide to hospitals, laboratories and
licensees. The company is headquartered
near Berlin, Germany with wholly
owned subsidiaries in USA, France, Italy,
Austria, UK and Spain as well as distribution
networks in over 65 countries.
Since October 2009 B·R·A·H·M·S is part
of Thermo Fisher Scientific Inc., the
world leader in serving science.
B·R·A·H·M·S Diagnostic Biomarkers
deliver essential information to effectively
organize diagnostic processes as
well as medical treatment strategies
through simple blood tests. In the fields
of Thyroid Diseases, Infections, Cardiovascular
Diseases, Tumor Markers, Prenatal
Screening and several other indications
B·R·A·H·M·S Diagnostic Biomarkers
offer solutions meeting unmet diagnostic
needs in Intensive Care Units (ICU)
and Emergency Departments (ED). These
patent protected biomarker test procedures
are available as manual assays,
fully automated laboratory test systems
or in a Point of Care format. B·R·A·H·M·S
Diagnostic Biomarkers benefit patients,
doctors and health care economy.
B·R·A·H·M·S’ key product PCT (Procalcitonin)
is a test for the early detection of
severe bacterial infections like the sepsis.
It enables ICU physicians to determine
whether an infection is bacterial
or viral in nature and provide actionable
information on the severity of a
patient‘s condition less than an hour
after a blood sample is drawn.
Another product, the novel cardiac
marker Copeptin, allows in combination
with Troponin a rapid and reliable rule
out of Acute Myocardial Infarction (AMI)
right at the initial blood draw when the
patient presents to the ED. By testing for
both markers, along with an Electrocardiogram
(ECG) and the clinical findings,
approximately two-thirds of the
patients would not need to wait up to
six hours in the ED for the second Tropo-
nin test. This may obviate the need for
prolonged monitoring and serial blood
sampling in the majority of patients.
MR-proANP prooved to be a highly useful
marker for diagnosing congestive
heart failure in patients presenting to
the ED with shortness of breath. ANP is a
natriuretic peptide predominantly produced
in the atrium of the heart. It is
involved in natriuresis, diuresis, vasodilation
and cardiovascular homeostasis.
The midregional portion of the pro-hormone
is termed as MR-proANP.
The cardiac marker MR-proADM shows
promise as a powerful predictor for
future cardiac events in patients with
a history of cardiovascular disease. The
predictive value of MR-proADM is additive
to prognostic information obtained
from existing classical risk models that
include traditional biomarkers such as
BNP and NT-proBNP. Adrenomedullin
(ADM) is a multifunctional peptide synthesized
by a variety of tissues including
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
heart and kidney. It regulates cardiopulmonary
function and vascular tone. MRproADM,
the stable midregion fragment
of ADM, is more readily measurable than
ADM, yet is secreted in equimolar quantities
and therefore provides an accurate
portrait of ADM release.
Address
B·R·A·H·M·S Aktiengesellschaft
Neuendorfstrasse 25
16761 Hennigsdorf · Germany
Contact
Ingo Buchholzer
Phone +49 3302 883 637
Fax +49 3302 883 635
i.buchholzer@brahms.de
www.brahms.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 47
LGC Genomics
1.4.2010 - AGOWA genomics becomes
LGC Genomics (www.lgcgenomics.com)
LGC Genomics is the division of LGC with
specific expertise in high quality, cutting-edge
genomic and related services
and products.
LGC is an international science-based
company and market leader in analytical,
forensic and diagnostic services and
reference standards.
The quality management system is certified
by DIN EN ISO 9001:2000.
Address
LGC Genomics GmbH
Ostendstrasse 25 • TGS Haus 8
12459 Berlin • Germany
Phone +49 30 5403 2200
service@lgcgenomics.com
www.lgcgenomics.com
PAREXEL International GmbH
PAREXEL International is a leading global
biopharmaceutical services organization,
providing a broad range of knowledgebased
contract research, medical communications
and consulting services to the
worldwide pharmaceutical, biotechnology
and medical device industries. Committed
to providing solutions that expedite
time-to-market and peak-market penetration,
PAREXEL has developed significant
expertise across the development and
commercialization continuum, from drug
development and regulatory consulting to
clinical pharmacology, clinical trials management,
medical education and reim-
1. Nucleic acid preparation
1.1. Nucleic acid extraction service
» DNA, RNA (manual & automated)
1.2. Automated DNA extraction
» sbeadex ® kits
» mag kits
» Magnetic particle manipulators
2. DNA sequencing services
» Single read sequencing
» Primer walking projects
» MTP sequencing (96/384 well)
3. Genomic services
» Next generation sequencing
(Roche/454 and Illumina GA2)
» Re-sequencing of genes
» Library services
» Cloning and sequencing
» Identification of microorganisms
» Genotyping services
» Bioinformatic services
bursement. Perceptive Informatics, Inc., a
subsidiary of PAREXEL, provides advanced
technology solutions, incl. medical imaging,
to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 71
locations throughout 50 countries around
the world, and has approx. 9,200
employees.
In Berlin, approx. 1,500 employees are
located today. Clients can benefit from
state-of-the-art technologies and equipment
provided through PAREXEL’s medical
imaging lab and Early Phase Units, which
provide a safe, high-quality environment
for early phase development activities in
a hospital setting. The PAREXEL Academy
qualifies clinical research associates and
clinical data managers, and offers a
course for a Bachelor of Science degree in
Clinical Research, validated by a British
university. PAREXEL also offers a Master’s
AGOWA genomics
becomes
Advancing genomic services
and products
Bild BioTopics 2010.indd 1 26.03.2010 09:48:46
studies program in Clinical Trial Management
in cooperation with the University
of Applied Sciences in Berlin.
Address
PAREXEL International GmbH
Klinikum Westend, Haus 18
Spandauer Damm 130
14050 Berlin · Germany
Contact
Dr. Ulf Schneider
Managing Director
Corporate Senior Vice President and CAO
Phone +49 30 30685 115
Fax +49 30 30685 7115
ulf.schneider@parexel.com
www.parexel.com

48
RiNA GmbH
RiNA Gmbh was founded 1998 as a
spin-off from the Institute of Biochemistry,
Free University of Berlin (Professor
Volker A. Erdmann). Together with
an excellent team of scientists, led by
an experienced Senior Executive (Leo
W. Tristram), RiNA successfully provided
major Research & Development in the
fi eld of prokaryotic and eukaryotic protein
expression systems.
Since 2002 RiNA Gmbh is engaged in
the fi eld of biotechnology and has
strengthened its position on the market
in research, product development and
production.
RiNA’s in house activities are focussing
on two major aspects
p Cell-free protein biosynthesis
RiNA’s protein biosynthesis group has
reached an internationally competitive
standard and RiNA aims to be one
of the world leading companies in the
fi eld of cell-free protein biosynthesis.
Customized
Systems
Kits
Individual Protein
Requirements
Protein
Expression
Service
Contract
Research
RiNA provides high quality proteins in accordance to the
Customers individual requirements.
The range of kits for cell-free protein
biosynthesis has been broadly expanded.
RiNA specifi cally provides
p Highly active cell lysates from bacterial
origin suited for the synthesis of
proteins up to milligram range.
p A methodology for the improvement
of protein solubility and functionality.
p Eukaryotic systems with the ability to
glycosylate proteins and to synthesize
functional membrane proteins.
p Kits for the rapid generation of linear
DNA templates with options to introduce
functional elements e.g. affi nity
tags, signal petides.
p A system for the site-specifi c labeling
of proteins, e.g. biotin, fl uorescence,
PEG, reactive groups.
p A special format for high throughput
expression in micro titer plates.
p An effi cient system for the in vitro
transcription enabling the synthesis
of milligram amounts of RNA.
In addition (September 2009) the complete
RTS Protein Expression portfolio of
Roche Applied Science was transferred
to RiNA GmbH. These RTS products are
now produced at the same quality standards
originally defi ned by ROCHE.
A dedicated specifi c Customer Service
for cell-free biosynthesis provides an
additional chance for RiNAs customers
to receive their desired (highly sophisticated)
protein utilizing RiNAs total
expertise.
p Functional RNA molecules
In this fi eld of nucleic acid, RiNA
develops customized nucleic acids
molecules as tools for environmental
analysis as well as for diagnostic
and therapeutic approaches. The
functional RNA group is expanding
its expertise in developing aptamers
(RNA/DNA), which have the property
to bind target molecules with high
affi nity and specifi city.
Recently, RiNA has developed a semiautomated
selection procedure for a fast,
reproducible, and parallelized aptamer
generation by using a robotic workstation.
This process will relieve the development
of aptamers and new aptamer
applications, e.g. aptamer biosensors.
Additionally, RiNA offers a customized
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
service for generation of aptamers and
is engaged in several research cooperation
projects.
Target Customer
Phase 1
Phase 2
Phase 3
In vitro selection
Aptamer
Aptamer Cloning and
Sequence Analysis
Phase 4
Characterization
of Aptamers
Address
RiNA GmbH
Takustrasse 3
14195 Berlin · Germany
Contact
Leo W. Tristram
Phone +49 30 8441660
Mobile +49 172 4360436
tristram@rina-gmbh.de
www.rina-gmbh.de
Production
and Delivery
The customized aptamer generation service of RiNA consists
of four phases for a maximum control of the project.

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 49
BLS Preclinical Services
BLS Preclinical Services is a contract
research organization (CRO) located in
Berlin. BLS provides a range of highquality
and integrated preclinical services
in animal models. Through our
highly skilled scientific partners we provide
a “one-stop” service and tailored
solution. We take the time to understand
your business needs and provide
comprehensive tailored solutions either
in-house or in co-operation of our net-
analyze & realize ag
analyze & realize ag, located in Berlin,
Germany, is a leading contract research
organization serving the biotech, pharmaceutical
and food industries. Over
35 highly skilled and experienced professionals
in the fields of food science,
nutrition, bio-chemistry, pharmacology,
medicine and marketing will focus on
exceeding your expectations.
analyze & realize ag is your preferred
partner when it comes to demonstrating
the functionality of your product. Being
an audited CRO, and a member of the
German Association for medical CROs,
we have conducted over 190 clinical trials
on functional foods, herbal products,
and dietary supplements.
work. We are backed by a highly skilled
scientific team with a wealth of experience
in all disciplines of preclinical
development.
We offer Medical Device Companies following
preclinical studies in small and
large animals:
p Proof of concept
p Medical device biocompatibility
testing
p Medical Device acute/chronic testing
p Medical device function testing
p Physicians hands-on training
We provide Pharmaceutical Companies
following services in animal models:
p ADME
p Efficacy
p Pharmacokinetic (PK)
p Pharmacodynamic (PD)
p Toxicology (acute and chronic)
p Behavior research
Take advantage of our in-house study
center with 5 physicians, a network of
over 50 experienced, specialized practitioners
and benefit from our strategic
alliances with the Charité hospital in
Berlin, Germany. Our expertise in food
regulations will help you to take advantage
of the different regulatory aspects
such as the Novel Food and Health Claim
authorization procedures.
We are always on top of the constantly
changing regulatory landscape of the
European market. Our value added services
include: regulatory consulting, gap
analysis, dossier preparation, dossier
evaluation and dossier submission.
We work closely with our clients to provide
tailored solutions to their preclinical
needs.
Address
BLS Preclinical Services
P.O. Box 191913
14008 Berlin · Germany
Contact
Christian Lange
Phone: +49 30 3230 4296
lange@bls-germany.com
www.bls-germany.com
Address
analyze & realize ag
Waldseeweg 6
13467 Berlin · Germany
Contact
Michael Faber
Head of Business Development
Phone +49 4000 8126
mfaber@analyze-realize.com
www.analyze-realize.com

50
Analytisches Zentrum Biopharm GmbH Berlin (AZB)
AZB is a German GLP-certified contract
research organization with long experience
in bioanalytical and pharmaceutical
analysis for human and veterinary
medication. As a service-provider, the
company offers solutions for pharmaceutical
analysis and bioanalysis for
active pharmaceutical ingredients (API)
in the dosage form, analytics for batch
release, quantitative determination of
analytes in biological matrices and the
determination of physicochemical
parameters of intermediates of the
chemical industry in agreement with
the OECD guidelines.
Pharmaceutical stability studies on
medicinal products and APIs are
achieved according to ICH and in compliance
with GMP. AZB has expert knowledge
in analysing human pharmaceuticals
(solid and semisolid oral dosage
forms, liquids, suppositories), veterinary
pharmaceuticals (powders, solid dosage
forms) and API which are subject to the
Addictive Drugs Act. The equipment and
know-how for analysing cytostatika is
available. The company provides e.g.
the development and validation of
methods indicating stability of content
and purity and the deposition of test
samples under ICH conditions as a service
for their customers. Analysis is carried
out according to the clients test
protocols or to the company-owned test
protocols. Deposition, control of storage
conditions and analysis are organized
and documented in compliance with
GMP. All excel sheets used for calculation
are validated in agreement with the SOP
system and GAMP5.
For bioanalytical studies for human
and veterinary pharmaceuticals, a large
pool of validated methods is available
for both the determination of APIs in
plasma and urine and in edible tissues
and milk of farm animals. Quantitative
determination of analytes in plasma of
farm animals and also quantitative
determination in medicated feed or
milk replacers, also in the context of
proof of stability, are likewise possible.
All methods are validated according to
relevant guidelines, e.g. the Guidance
for Industry: Bioanalytical method validation.
The procedures are continuously
developed. Thus, AZB has already shortened
the time of analysis in some
methods by using short HPLC columns
with constant precision and accuracy.
Analytical techniques available for
assays are HLPC with UV, fluorimetric and
electrochemical detection, LC/MS, LC/MS-
MS and GC/MS.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
AZB carries out the determination of
physicochemical properties under GLP
in accordance with OECD guidelines.
Quality assurance
AZB has an independent quality assurance
unit under GLP guidelines that
keeps a high quality standard up-todate.
All equipment used is qualified
and is subject to the lifetime model. The
quality assurance system is officially
certified (test category 1 and 8) and has
been confirmed by numerous audits.
Address
Analytisches Zentrum Biopharm GmbH
Bitterfelder Strasse 19
12681 Berlin · Germany
Contact
Dr. rer. nat. Ulrich Kunter
Head of the test facility
Phone +49 30 93652140
Fax +49 30 93652220
info@az-biopharm.de
www.az-biopharm.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 51
Biochrom AG
Biochrom AG is a company dedicated to
be a primary supplier of cell culture
media and quality animal sera.
The company manufactures and distributes
the full range of products related to
mammalian cell culturing technique:
standard cell culture media, complete
media tailored for particular cell types
and cell lines, custom formulations, and
animal sera, such as Fetal Bovine Serum
(FBS). All sera are prescreened prior to
acceptance; only those lots that meet
strict quality control requirements are
ProteaImmun GmbH
ProteaImmun is a proteomic company
and was founded on September 2009 as
a spin-off of Invitek GmbH and therefore
has a long expertise in ELISA and
recombinant protein expression, especially
with human proteases, substrates
and analysis of proteins. Our core competence
is a broad knowledge in cell
culture, protein purification and development
of assays. This enables Protea-
Immun to offer customized solutions
and support with single components as
accepted for further processing and subsequent
sale to customers. Serum products
are tested for sterility, adventi tious
viral agents, physico-chemical parameters,
and biological performance. The
manufacturing processes are de signed
for the specific needs of customers
engaged in biotechnological research,
development, and biopharmaceutical
production. Biochrom AG specializes in
meeting customers‘ specifications and
regulatory concerns, to facilitate the
manufacture of custom media consistent
with Good Manufacturing Practice (GMP).
The media are produced in a strictly controlled
environment; chemicals used
conform, where applicable, to grade
standards of European Pharmacopoeia
and US Pharma copoeia. Biochrom AG
produces lot sizes of industrial buffers up
to 4,000 litres, powder media up to
20,000 litres and customized sizes in
smallest quantities.
well as with complete molecular diagnostic
systems. ProteaImmun supports
the integration of new biomarkers for
neurological diseases, bone disorders in
molecular diagnostics and therapy. The
establishment of the interface between
these two areas poses a challenge for
molecular biological research and development
as well as for the biotechnological
industry. ProteaImmun emphasizes
on difficult-to-express proteases as
human MMPs (Matrix Metalloprotein-
Biochrom AG and TPP Techno Plastic
Products AG (Switzerland) are exclusive
partners for the sale of TPP products for
cell culture and general laboratory
equipment in Germany.
Address
Biochrom AG
Leonorenstraße 2-6
12247 Berlin · Germany
Phone +49 30 779 90 60
Fax +49 30 771 00 12
info@biochrom.de
www.biochrom.de
ases), human ADAMTS (A Disintegrin And
Metalloprotease with Thrombospondin
motifs) and human HtrAs (High temperature
requirement factor A), which play
an important role in diseases as cancer,
Alzheimer as well as rheumatic and cardiovascular
diseases.
Address
ProteaImmun GmbH
Robert-Roessle Straße 10 / Haus 85
13125 Berlin · Germany
Contact
Tatiana Teixeira-Schneider
(Sales & Marketing Manager)
Phone +49 30 9489 3170
Fax +49 30 9489 3172
schneider@proteaimmun.de
www.proteaimmun.de

52
provitro GmbH
Provitro stand for more than a decade of
biotechnological expertise in high-quality
analytical services, tissue microarrays,
cell cultures, culture media and
cytokines. Based at the Campus Charité
Mitte in Berlin we combine medical
research excellence and profound experience
in biotechnology to create convincing
solutions and applications for
life science research and development.
We focus on the interface of R&D providing
our global university and industrial
customers with state-of-the-art prod-
ucts and unique services to match their
individual needs.
Tissue Microarrays
With more than 200.000 samples provitro
operates a large human tissue bank giving
us the resources to meet nearly every
demand. Our unmatched tissue microarrays
with up to 140 individual FFPE
tissue samples on a single slide minimize
variations in staining intensity. Yielding
consistent results they are ideal for morphological
evaluation and rapid localization
of DNA or protein molecules in a
variety of human tissue samples.
Analytical Services
In addition, provitro has an exceptional
standing in a wide range of flexible analytical
services. Starting with the development
of protocols for both manual and
automated immunohistochemical staining
and target validation with antibodies
on normal and tumour tissue samples
from our extensive tissue bank right
through to certified in-process quality
control systems (iCon TMA ® ) to verify the
specificity of antibody reaction.
Primary Cell Cultures and Culture Media
As a supplier of premium life science
products our strictly controlled primary
cell cultures are isolated from various
tissues of human origin and shipped
with a batch-specific analysis certificate.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
The culture media provided as a set of
basal medium and supplements contain
all necessary growth factors specific to
each cell type.
So if you are looking for a reliable partner
who is as innovative as your research
project please contact us:
Address
provitro GmbH
Campus Charité Mitte
Charitéplatz 1
10117 Berlin • Germany
Contact
Dr. Manrico Paulitschke
Phone +49 30 450578352
Fax +49 30 450578952
office@provitro.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 53
NOXXON Pharma AG
NOXXON Pharma AG is a clinical-stage
private biotechnology company focusing
on the development of its proprietary
substance class Spiegelmers (L-aptamers)
for the treatment of inflammatory diseases
and hematological indications.
Spiegelmers are mirror-image oligonucleotides
designed to bind and inactivate
proteins that cause disease. The company
currently targets various disease
Glycotope GmbH
Glycotope has developed a unique and
regulatory approved platform technology
for the development and production
of NBEs and improved second generation
biopharmaceuticals / BioBetters.
This toolbox of human cell lines allows
the manifold improvement of key clinical
properties (such as activity, availability,
immunogenicity) for both antibodies
and non-Ab proteins via targeted alteration
of the glycosylation. With excellent
production features, GlycoExpress
is also the base of Glycotope´s pipeline
of currently 4 therapeutic antibodies –
areas with its proprietary development
programs: diabetes and related complications
with an underlying inflammatory
component, such as diabetic
nephropathy; hematopoietic stem cell
mobilization and/or haematological and
solid tumors; and anemia of inflammation.
NOXXON drug candidates NOX-E36
and NOX-A12 were shown to be safe and
well tolerated in phase I clinical trials
and displayed promising pharmacodynamic
effects.
In addition to its in-house programs
NOXXON discovers and develops Spiegelmers
in collaboration with partners from
the pharmaceutical industry, including
Eli Lilly and Hoffmann La-Roche. The
declared goal of NOXXON is to establish
its oligonucleotide-based drug discovery
platform (Spiegelmers ® ) as the leading
‘scaffold’ technology to create new
chemical entities with superior properties.
the first of which has entered the clinic
in 2009 with the second to follow in
Q2/2010 – and 1 protein-hormone.
GlycoExpress
p Toolbox of glycoengineered human
cell lines
p Fully human & optimized
glycosylation
p Highly improved bioactivity,
bioavailability & immunogenicity
p Screening and high yield production
system
p New patent protection of products
Address
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin · Germany
Contact
Phone + 49 30 726247100
Fax + 49 30 726247225
edelabre@noxxon.com
www.noxxon.com
Pipeline of GlycoOptimized Products
p Proprietary NBEs & improved second
generation products
p Currently 4 antibodies,
1 protein-hormone
Via Glycotope Biotechnology:
p GMP-Production of biologics
p Fill & Finish of API and drug
Address
Glycotope GmbH
Robert-Roessle-Strasse 10
13125 Berlin · Germany
Phone +49 30 94892600
Fax +49 30 94892609
info@glycotope.com
www.glycotope.com

54
Evestra GmbH
Evestra GmbH, founded in July 2008, is
a fully owned subsidiary of Evestra Inc.,
located in San Antonio Texas. Evestra is
focused on the development of female
healthcare products for gynecological
indications such as fertility control,
hormone replacement therapy, endo-
BIOTECON Diagnostics GmbH
BIOTECON Diagnostics was founded in
1998 and currently has 45 employees.
The company provides superior experience
in microbiological service testing
of food, pharmaceutical and cosmetics
products.
The company’s focus is the development
of rapid and innovative detection
systems for pathogenic, spoilage and
genetically modifi ed organisms (GMO)
metriosis, and breast cancer. Key competency
of Evestra is development of
steroid-based products, including sexual
hormones. Evestra GmbH serves as
the development and commercialization
center for Europe and ROW.
Near-Term
Evestra‘s leading products are generic
and reformulation products based on
leading oral contraception products.
Regulatory submissions for three products
are planned between 2011 and
2012.
Longer-Term
Establish proof of concept Phase II data
for NCE’s in fertility control, breast cancer
and endometriosis. Evestra’s fi rst
innovative product is an oral contraceptive
which includes a novel estrogen
with potentially superior pharmacological
properties.
based on real-time PCR. The foodproof ®
product line includes detection kits as
well as sample preparation kits for the
extraction and purifi cation of DNA from
multiple food matrices.
As an international biotechnology company,
BIOTECON Diagnostics has been
developing, producing and marketing
these products through a continually
growing network of local distributors
and worldwide sales channel partners.
Due to close contacts to many companies
in the industry, BIOTECON Diagnostics
is well aware of customers’ current
and future challenges. The company
is able to provide fl exible solutions to
production and processing companies
through new and economical approaches.
Furthermore, BIOTECON Diagnostics
also offers contract development and
production to other biotech companies.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Address
Evestra GmbH
Grünlingweg 20
12351 Berlin · Germany
EU Contact
Prof. Klaus Nickisch
Managing Director
Phone +49 30 66509642
knickisch@evestra.com
www.evestra.com
Caring for Women’s Health ®
For safer food: BIOTECON Diagnostics –
simply builds up trust.
Address
BIOTECON Diagnostics GmbH
Hermannswerder 17
14473 Potsdam · Germany
Contact
Kornelia Berghof-Jäger, Ph. D.
Chief Executive Offi cer
Alois Schneiderbauer
Chief Business Offi cer
Phone +49 331 2300200
Fax +49 331 2300299
bcd@bc-diagnostics.com

Career Gateway
Stuttgart - Düsseldorf - München
Meeting Point
Stellenmarkt online
Elektronisches Firmenportal
Jahrespublikation mit Branchenberichten
www.t5-futures.de
Pharmazie Medizintechnik Biotechnologie Chemie Life Sciences Umwelttechnologie

As your integral technology partner we add our global biotechnological/pharmaceutical expertise to your
processes in order to reduce your time to market while assuring the highest quality standard. Our expertise,
the profound knowledge of the needs and particularities in the biotechnological/pharmaceutical industry and
the ambition to provide individually customized solutions, is rooted in our origin as a Bayer company. With this
heritage and our present-day network of multiple locations on all major continents as well as our innovative drive
we are prepared to accompany you on the way to success – Powering Your Performance.
Our most recent technologies for your optimal process include
Bayer Technology Services GmbH
51368 Leverkusen, Germany
E-mail: info@bayertechnology.com
www.bayertechnology.com

Addresses
ddresses
Networks 58
Biotech Parks 59
IP Asset Management 59
Universities and Research Centers 59
Banks and VCs 60
Supporting Organisations 60
Pharmaceutical Companies 61
Contract Research Organisations 62
Biotech Companies 63

58
Networks
BioHyTec – Verein für Bioanalytik
und Biohybrid-Technologien e.V.
BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Brandenburg.
This new field of technology is the interface between biosensor development and microsystems
technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diagnostics,
food analysis and genetic engineering.
BioResponseNetzwerk BioResponse is an interdisciplinary research and development organisation with members from
Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays
for diagnostic antibody identification based on the proprietary BioResponse technology, which is
comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled
cell structures.
DiagnostikNet-BB Netzwerk Diagnostik
Berlin-Brandenburg
GABI – Genomanalyse im Biologischen
System Pflanze
DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro diagnostics. Members include biotech
companies as well research institutes and clinics. Main objectives of the network are: Development
of system solutions, optimizing compatibility, close cooperation with leading clinicians and
joint marketing.
GABI stands for Genome Analysis of the Plant Biological System and is an associative project supported
by the German Federal Ministry of Education, Research and Technology (BMBF) as well as a
number private enterprise companies. These companies are grouped under the Business Platform
promoting Plant Genome Research GABI e.V. (WPG). A Patent and Licence Agency associated with
GABI (GVS) has the task of commercialising and protecting research results by means of licence
rights.
Glykostrukturfabrik The Network Glycobiotechnology Berlin-Brandenburg brings together scientists with many different
areas of competence in studying and utilizing complex carbohydrates. The aim is product-oriented
development of the region’s wide range of glycobiological technologies, building a complete glycobiotechnological
process chain and to establish the region as a center of competence in the field of
glycobiotechnology.
Health Capital Berlin-Brandenburg In order to develop the scientific and economic position of the region, the governments of the
states of Berlin and Brandenburg have put the master plan „Healthregion Berlin Brandenburg“ into
effect. Its key to a continued success is a continued close interplay between research, development
and education / vocational training with production, application and supply. All of these activities
are integrated and coordinated through the Network „Gesundheitswirtschaft Berlin Brandenburg“
under the brand of „HealthCapital“.
Net-DDD Network for Drug Discovery &
Development Berlin-Brandenburg
Netzwerk Nutrigenomik
Berlin-Brandenburg
Netzwerk Weiße Biotechnologie
Berlin-Brandenburg
The Network for Drug Discovery & Development Berlin-Brandenburg was launched in 2007 as an
open interdisciplinary initiative with the aim to accelerate the transfer of clinical relevant findings
into innovative drugs and therapeutic concepts. The network, which was co-founded by the
Leibniz Institut für Molekulare Pharmakologie (FMP) and the competence network biotechnology,
BioTOP Berlin-Brandenburg, offers state-of-the-art technology and expertise in the field of drug
discovery.
Nutrigenomics is a highly innovative and fast-growing interdisciplinary field of research linking
genome research, plant biotechnology and molecular nutritional research and offering new
applications for medicine and nutrition. Nutrigenomics aims at providing an understanding for
how nutrition affects the balance between health and disease. Network partners include local
universities and research institutes, private enterprises, public-sector organizations and various
collaborative project groups.
The White Biotechnology Network serves as an engine for the advancement of the white biotechnology
in the Berlin-Brandenburg region. By combining of a number of competencies, the partners
in the network are capable of developing innovative solutions for complex problems in den fields
of chemistry, paper, cosmetics, pharmaceuticals and food.
Regenerative Medicine Initiative Berlin The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of excellence
for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes
networking in the field and supports the further development of clinical studies and education
programs. The initiative fosters the collaboration between universities, research institutes, companies
(including SMEs) and organizations in the field of science and technology.
RiNA -Netzwerk RNA-Technologien The RNA-Network provides ongoing support and funding for the development of RNA technologies
with the goal to commercialize the results. One main focus is the improvement and application of
the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis
systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network
encourages co-operation and information exchange between academy and industry.
Ultrastrukturnetzwerk The Ultra Structure Network brings together researchers in the field of structural proteomics with the
aim of conducting high-throughput analysis of supramolecular structures using mass spectrometry
(MS) and cryoelectron microscopy.
Zentrum für Molekulare Diagnostik und
Bioanalytik
The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated under the
auspices of the Fraunhofer Institute for Biomedical Technology and the Charité – Universitätsmedizin
Berlin in close cooperation with the region’s company networks. The aim is to bring together
regional expertise in basic research, technology development, clinical research and industrial cooperation
initiatives to set up joint projects that will speed up the development of in vitro diagnostics
“Made in Berlin-Brandenburg”.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
biohytec.de
bioresponse.de
diagnostiknet-bb.de
gabi.de
glykostrukturfabrik.de
healthcapital.de
drugdiscoverynet.de
nutrigenomik.de
weisse-biotechnologiebb.de
rmib.de
rna-network.com
ultrastrukturnetzwerk.de
zmdb.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Parks
berlinbiotechpark berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently offering a
total of approx. 57,000 m² of office, laboratory and production space, with a building potential for
another 45,000 m² of rental area. Offering flexible growth potential, production-orientated media
equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is
particularly attractive for growing internationally orientated technology companies.
Biotech Campus Potsdam Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, BIOTECH
CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and
operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of
the State of Brandenburg.
Biotechnologiepark
Luckenwalde
Biotechnologiezentrum Hennigsdorf
co:bios Technologiezentrum GmbH
Campus Berlin-Buch
bbb Management GmbH
Adlershof Zentren für Biotechnologie
und Umwelt
Other Parks
Science Park Potsdam-Golm
GO:IN Golm Innovationszentrum GmbH
Innovationspark Wuhlheide
Managementgesellschaft mbH
IP Asset Management
Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International Airport
in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most
modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from
Germany, USA, UK, Korea, India, Italy and Russia.
On the northern perimeter of Berlin, a number of biotech and medtech companies have
been established at the BiotechnologieZentrum Hennigsdorf around the diagnostics company
B.R.A.H.M.S. The BiotechnologieZentrum Hennigsdorf was set up in 2001. It offers full service for
small and mid-sized biotech companies.
Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 square
meters of scalable lab and office space for start-ups and maturing companies. Situated to the
northeast of the city, the campus is currently home to 49 companies, 35 of which are biotech
companies; the rest provide support services.
Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on Photonics
and optical technologies, material and microsystems technology, information and media technology,
biological, environmental and energy technology. There are currently 25 biotech companies
in Adlershof occupying 18,200 sq.m of lab and office space.
Science Park Potsdam-Golm is one of the most innovative and promising locations in Brandenburg.
In the GO:IN facility, innovative companies will find an excellent working environment where
they will benefit from the synergy effects of the location and the specific equipment offered by its
laboratories. The location provides a wide range of services and consulting, as well as integration
into the existing regional networks.
On the 80,000 acre Technology Campus Innovation Park Wuhlheide, small and medium-sized
companies will find perfect conditions to pursue their ideas and business goals. The companies
working on the Campus come from a variety of disciplines and sectors and are mainly technologyoriented.
Ascenion Ascenion advises public life science research institutions, universities, hospitals, freelance inventors
and companies in all aspects of intellectual property asset management.
ipal GmbH intellectual property
asset management
ZukunftsAgentur Brandenburg
GmbH Brainshell
Universities and Research Centers
ipal assesses and markets the inventions of Berlins university scientists and academics on an exclusive
basis and is financed by the Berlin universities as well as the Investment Bank Berlin (IBB).
Cooperation agreements exist with Charité, RKI, PEI, BAM and other excellent research institutes.
Brainshell is an independent consulting agency specializing in intellectual property services for
businesses.Brainshell manages and markets the patent portfolios of all colleges, universities, and
research institutes in the State of Brandenburg.
berlinbiotechpark.de
biotechcampus.de
bio-luck.de
cobios-
technologiezentrum.de
bbb-berlin.de
wista.de
wissenschaftspark-potsdam.de
goin-potsdam.de
ipw-berlin.de
ascenion.de
ipal.de
brainshell.de
BAM Federal Institute for Materials Research and Testing bam.de
Berlin-Brandenburg Center for Regenerative Therapies b-crt.de
Berlin Institute of Technology tu-berlin.de
BfR Federale Institute for Risk Assessment bfr.bund.de
Brandenburg University of Technology tu-cottbus.de
Charité - Universitätsmedizin Berlin charite.de
Deutsches Rheuma-Forschungszentrum Berlin drfz.de
Fraunhofer Institute for Applied Polymer Research (IAP) iap.fhg.de
59

60
Universities and Research Centers
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Fraunhofer Institute for Biomedical Engineering (IBMT) ibmt.fraunhofer.de
Freie Universität Berlin fu-berlin.de
German Heart Instiute Berlin dhzb.de
German Institute of Human Nutrition (DIfE) dife.de
Humboldt-Universität zu Berlin hu-berlin.de
Institute of Polymer Research of the GKSS Research Centre gkss.de
Institute for the Reproduction of Farm Animals Schönow Inc. ifn-schoenow.de
Lausitz University of Applied Sciences fh-lausitz.de
Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) atb-potsdam.de
Leibniz-Institut für Molekulare Pharmakologie (FMP) fmp-berlin.de
Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch mdc-berlin.de
Max Planck Institute for Infection Biology mpiib-berlin.mpg.de
Max Planck Institute for Colloids and Interfaces mpikg-golm.mpg.de
Max Planck Institute for Molecular Genetics molgen.mpg.de
Max Planck Institute of Molecular Plant Physiology mpimp-golm.mpg.de
Robert Koch Institute (RKI) rki.de
University of Applied Sciences Berlin beuthhochschule.de
University of Applied Sciences Wildau th-wildau.de
University of Potsdam uni-potsdam.de
Banks and VCs
BC Brandenburg Capital GmbH bc-capital.de
Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge lbb.de
Berliner Volksbank eG berliner-volksbank.de
bmp Life Science AG bmp.com
Business Angels Club Berlin e.V. business-angels-berlin.de
CCM Columbus Capital Management columbusco.com
Commerzbank AG commerzbank.com
Creathor Venture creathor.de
Deutsche Bank AG db.com
High-Tech Gründerfonds Management GmbH high-tech-gruenderfonds.de
IBB Beteiligungsgesellschaft mbH ibb-bet.de
Investitionsbank Berlin ibb.de
Investitionsbank des Landes Brandenburg ilb.de
KfW-Mittelstandsbank kfw-mittelstandsbank.de
Peppermint Financial Partners GmbH PEPPERMINT-vc.de
Triginta Capital triginta-capital.com/life-science.htm
Supporting Organisations
Berlin Partner GmbH Support of international and domestic companies in all issues regarding locating to Berlin berlin-partner.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Supporting Organisations
BioTOP Berlin-Brandenburg BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning
biotechnology in the German capital region.
Investitionsbank Berlin (IBB) Company financing and consultation on subsidies and processing grant applications in Berlin. ibb.de
Investitionsbank des
Landes Brandenburg
Landesamt für Gesundheit
und Soziales Berlin (LAGeSo)
Company financing and consultation on subsidies and processing grant applications in Brandenburg.
One Stop Agency for all licensing and approvals, for questions concerning biomedicine, biotechnology
and pharmaceuticals and for more general issues connected with health, disease control and
public health in Berlin
biotop.de
ilb.de
berlin.lageso.de
TCC Technologie Coaching Center Specific Coaching offers for innovative high tech companies tcc-berlin.de
Technologie Stiftung Brandenburg The technology Foundation Brandenburg is dedicated to the advancement of science and research,
especially in the field of innovative technologies.
TSB Technologiestiftung Berlin Gruppe The TSB Technology Foundation Berlin Group is a public private partnership in the German capital
region to develop science and industry networks for technology transfer, joint projects, and
regional innovation strategies.
TSB Innovationsagentur Berlin GmbH The TSB Innovation agency supports small and medium-sized companies in the management of
innovation processes.
ZAB Zukunftsagentur Brandenburg The Brandenburg Economic Development Board functions as a one-stop agency for all kinds of
business support services.
ZAK Zentrale Anlauf- und Koordinierungsstelle
Senatsverwaltung für
Wirtschaft, Arbeit und Frauen
Pharmaceutical Companies
Helps you find your way through the Berlin administration. Supports complex urban development
policy and investment projects.
Bausch & Lomb Dr Mann Pharma Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for
consumers around the world. Core businesses include soft and rigid gas permeable contact lenses
and lens care products, and ophthalmic surgical and pharmaceutical products.
Bayer Schering Pharma
Aktiengesellschaft
Bayer Schering Pharma is one of the ten largest specialty pharmaceutical companies in the world
and the company‘s goal is a leading market position in each of its specialist fields. With its distinctive
expertise in research, the company develops new medicines and therapies which make an
essential contribution toward improving patient‘s quality of life
BERLIN-CHEMIE Aktiengesellschaft BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was formed in
1886 and is headquartered in Florence, was developed over the generations to become a global,
owner-managed pharmaceutical company. Research is centred on the development of innovative
drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology,
viral disease.
CT Arzneimittel GmbH CT Arzneimittel is a pharmaceuticals company that focuses on generics production. Prescription
medicines form the bulk of the product portfolio, which includes some 1,200 drugs with more
than 200 different active agents that are used to treat the most common clinical syndromes.
Dr. Kade Pharmazeutische Fabrik GmbH The company’s activities concentrate on the production and marketing of drugs in the fields of
gynecology, proctology, pain relief/ rheumatism and urology. The potential of proven drugs is
expanded systematically by galenic developments to produce innovative products.
Heyl chemisch pharmazeutische
Fabrik GmbH & Co. KG
HEYL is an independent, entrepreneurial family business that has its headquarters in Berlin, since
its establishment in 1926. In cooperation with its international subsidiaries, the main focuses of
the work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical
ingredients (API‘s) and special chemicals.
Intendis GmbH Intendis is a specialized pharmaceutical company focused on the Dermatologicals category.
Headquartered in Berlin, Germany the company was founded in 2005 as a subsidiary of Schering
AG. Intendis has a successful track record of providing prescription drug products for the treatment
of severe skin diseases and was a pioneer in the development of locally applicable corticosteroid
treatments.
Klosterfrau Berlin GmbH For more than 175 years Klosterfrau has been developing, manufacturing and marketing pharmaceutical
products. The profile of traditional yet modern natural medicines has grown significantly
in recent times. Based on the latest scientific discoveries combined with the development of new
markets, the range is constantly being expanded with innovative products.
medphano Arzneimittel GmbH medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical preparations.
The main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs
to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expectorants,
lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods.
MUCOS Pharma GmbH & Co.KG As a specialist in enzyme preparations Mucos supplies a steadily growing market with specific and
variably dosed enzyme combinations. The company leads the world market in oral enzymes for
therapeutic purposes.
ts-bb.de
tsb-berlin.de
tsb-berlin.de
zab-brandenburg.de
berlin.de/sen/wirtschaft/
zak/wir
bausch-lomb.de
bayerscheringpharma.de
berlin-chemie.de
ct-arzneimittel.de
kade.de
heyl-berlin.de
intendis.com
klosterfrau.de
medphano.de
mucos.de
61

62
Pharmaceutical Companies
Nycomed Oranienburg GmbH As the competence centre for the development, production and packaging of solid dosage formulations
Nycomed Oranienburg plays an important part in the global Nycomed operations network.
It supplies the global pharmaceutical markets in more than 100 countries, from Europe to the US
and Japan. The products include corporate Nycomed products and contract manufacturing for third
parties.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
nycomed.de
Pfizer GmbH Pfizer is the world‘s largest research-based biomedical and pharmaceutical company. pfizer.de
Sanofi-Aventis Deutschland GmbH Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating in over
100 countries. R&D teams work on a global approach to patients, offering innovative therapeutic
strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous
system disorders and internal medicine.
Shire Deutschland GmbH Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses
on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and
hyperactivity disorder, human genetic therapies and gastrointestinal diseases.
Steiner & Co. Deutsche Arzneimittelgesellschaft
mbH & Co. KG
Steripharm Pharmazeutische
Produkte GmbH & Co. KG
Contract Manufacturers
Production and marketing of pharmacy and prescription drugs, particularly plant-based drugs
(tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and
urological drugs), analgesics and mineral preparations.
sanofi-aventis.de
shire.com
steinerarznei-berlin.de
Production and marketing of folic acid products steripharm.de
Advance Pharma GmbH Contract manufacturer of solid drugs.Galenic development and admissions, analytics and microbiology,
coating and granulation (organic and aqueous), compacting, packaging.
ALPHAMADE GmbH Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding,
omega-3 fatty acids, cytostatics
Chemisch-pharmazeutisches Labor,
Rolf Sachse GmbH
CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients (API’s); Contract
manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical
analysis
Gelkaps GmbH Contract manufacturer focussing on the development and production of soft gelatine capsules
under GMP conditions. The product portfolio ranges from food supplements to dietary products and
pharmaceuticals.
Haupt Pharma AG With nine production sites Haupt Pharma is one of the leading contract manufacturers for pharmaceutical
products in the world today. About 2.000 employees produce for an established clientele
of more than 200 important international pharmaceutical companies, amongst which 15 of the
international TOP 25.
Pharma Action Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing
since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and
abroad.
Spreewälder Arzneimittel GmbH Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements,
diet foods and cosmetics in liquid, semi-solid and solid administration forms.
Contract Research Organisations
Assign International GmbH Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with six
offices in five countries.Our expertise meets development requirements of pharmaceutical and
biotechnological industries. We manage clinical trials from study set-up to final clinical report.
Our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems,
Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management.
BLS Preclinical Services BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS provides a
range of highquality and integrated preclinical services in animal models. Through our highly
skilled scientific partners we provide a “one-stop” service and tailored solution. We take the time
to understand your business needs and provide comprehensive tailored solutions either in-house
or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth
of experience in all disciplines of preclinical development.
Charité Research Organisation GmbH Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration with Berlin‘s
famous Charité University Hospital. This relationship fosters a level of cooperation with centers of
clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to
the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical
expertise and specialist methodologies in support of early clinical development programs.
Cooperative Clinical Drug Research
and Development (CCDRD) AG
CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to offer creative
and innoative full service from planning to market authorization to its customers in the pharmaceutical,
biotechnological and medical device industry.
advance-pharma.eu
alphamade.de
cpl-sachse.de
gelkaps.de
haupt-pharma.de
Pharma-action.com
spreewaelder-
arzneimittel.de
assigngroup.com
bls-germany.com
charite-research.org
ccdrdag.com

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Contract Research Organisations
CSG Clinische Studien Gesellschaft mbH Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on aligning
clinical research with public health demands, with special attention to facilitating access by physicians
and patients to clinical studies.CSG cooperates closely with the largest research institute for
public health in Germany, the IGES Institut.
Dr. Notghi Contract Research Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized companies
in the pharmaceutical, generics and biotechnology industries. We support and advise you in
the conduct and management of national and international projects.
Klinische Forschung Berlin GbR Klinische Forschung Berlin is a study centre that implements clinical studies from phases IIA to IV
for the pharmaceuticals industry.
Klinische Forschung Gruppe Nord
GmbH
The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of independent
investigator institutes with five centres in Northern Germany, two of them in Berlin.The Klinische
Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are
the core competence. The test centres have altogether 30 overnight accommodation places for
phase I and IIa studies.
PAREXEL International GmbH The German subsidiary of the US clinical research organization PAREXEL employs more than 1,400
people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual
enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed
each year.
Biotech Companies
3B Pharmaceuticals GmbH 3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin,
Germany. The company is dedicated to the development of peptide-based pharmaceutical- and
diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine.
8sens.biognostic GmbH 8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for different
markets (human and veterinary diagnostics, food control). Our products are the QuickSens ® -tests
for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification QuickSens ® OMEGA. Development-on-demand,
feasibility studies and production-on-demand are also offered.
ABiTEP GmbH The ABiTEP GmbH is working in development and production of biotechnological products for
sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific
technologies in laboratory scale and scale up with modern equipment and Know how. Capacities
for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90
L are available for services.
AFOSA GmbH Development, production and marketing of diagnostics (ELISA kits), primarily for use in veterinary
medicine
Aglycon Mycoton GmbH Aglycon Mycoton GmbH is active in the research, development and application of biopolymers as
well and their manufacture and the sales and marketing of products based on these.
AJ Innuscreen GmbH AJ Innuscreen GmbH, a young life science company, boosts the bio solutions business unit as part
of the Analytik Jena Group. Innovative technologies and products are developed and produced for
the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as
technologies and products for molecular diagnostics, are also included in the product portfolio.
Alcat Europe GmbH Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original developer
of the Alcat test technology. The company is specialized to identify intolerant reactions of the
leucocytes to foreign substances like foods, drugs or chemicals.
Alrise Biosystems GmbH ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of active
ingredients. Using its globally patented ImSus ® technology, ALRISE are developing parenteral
deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly
large pharmaceutical companies who are developing improved administration forms for active
ingredients whose patents are expiring together with ALRISE as part of their "Product Lifecycle
Management".
Amocol Bioprocedures Ltd. Amocol Bioprocedures Ltd is a Life Science Research & Development and Manufacturing Company
headquartered in Germany. Our mission is to supply innovative affinity chromatography media
products and protein purification tools for research scientists and clinical customers in public sector
institutes and industry.
Anagnostec GmbH AnagnosTec GmbH develops and sells products and services based on MALDI-TOF mass spectrometry.
p SARAMIS Software and Database for Identification of Microorganisms p Development of mass
spectrometry analyses of complex biological materials p Natural product screening, polymer analysis
and peptide analysis p Mass-spectrometric quality control of single and multi-step organic p
Development of intelligent software solutions to handle and interpret mass spectrometric data
AnaKat Institut für Biotechnologie
GmbH
AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of pharmaceutical
ingredients.
csg-germany.com
notghi.com
klinische-forschung-
berlin.de
kfgn.de
parexel.com
3b-pharma.com
biognostic.de
abitep.de
afosa.com
aglycon-mycoton.net
innuscreen.com
alcat-europe.com
alrise.de
amocol.com
anagnostec.de
anakat.de
63

64
Biotech Companies
Analyticon Discovery GmbH AnalytiCon is a biotechnology company focusing on the development of compound libraries
consisting of natural product (NP) and synthetic small molecules. As the global market leader in
NP small molecule screening compounds, AnalytiCon is the only company which is able to provide
vast collections with completely disclosed structural information. As a pure compound provider the
company is offering its products and services to the pharmaceutical, chemical, biotech, cosmetical
and nutraceutical industry.
Analytisches Zentrum Biopharm Berlin
GmbH
Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing services
on pharmaceutical analysis and bioanalysis for active compounds in the dosage form, for the
quantitative determination of analytes in a biological matrix and also the determination of physicochemical
parameters of chemicals according to OECD guidelines. AZB carries out these services in
compliance with GLP and GMP and has the GLP certificate.
AnaTox GmbH & Co. KG The AnaTox GmbH & Co. KG deals with the development and optimization of analytical methods
and devices for HPLC and dissolution.
ANiMOX GmbH Development of applications for the use of natural peptide / amino acid mixtures in chemistry and
biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations, foaming or
hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution
of a technology for the production of such basic materials from raw and residual materials.
aokin AG aokin AG is a Berlin biotechnology company that is specialized in the development and commercialization
of innovative analytical systems on the base of the rapid kinetic assay technology. The
aokin systems are unique in their precision and operating speed. Areas of application are food and
antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of
food analytics, Pharmacoanalytics and chemical synthesis.
AptaRes AG AptaRes is a developer and manufacturer of aptamers as an alternative to antibodies. The aptamers
are isolated in vitro by using a proprietary technology. AptaRes is also developing aptamer-supported
processes and analytical methods. It provides also consumables required for the aptamer
applications. In collaboration with financial partners AptaRes supports with its enabeling technology
entrepreneurs and the expansion of biotechnology companies.
ARGUS Umweltbiotechnologie GmbH ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation of
contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific
remediation program in each different pollution case considering economic aspects beside
ecological aspects. All necessary treatment steps can be planned and carried out. The combination
of microbiological steps with classic processes leads to a successful remediation of complex
contamination.
ASCA GmbH
Angewandte Synthesechemie
Adlershof GmbH
ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis and
optimization of lead structures, the development of new active structures and their check on a
laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid
preparations and exact analysis of the samples. All our results are carefully documented for our
customers. Access to literature databases and in-house analytical facilities are available.
Astra Biotech GmbH The Company Astra Biotech offers a wide range of high-quality reagents and diagnostic kits. The
catalogue provided by our company includes reagents for detecting of human hormones, genetic
diseases, tumor markers and allergens.Besides, we develop cutting-edge, technologically perfect
solutions in the field of diagnostics and we are ready to offer our experience, skills and knowledge
for realization of your projects.
ATLAS Biolabs GmbH ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as genome
wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors
and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises.
Attomol GmbH Molekulare Diagnostika The company's aim is to develop, produce and distribute medical diagnostics for human medicine
in the field of molecular genetics, infectious and autoimmune diseases.
AutoTissue GmbH The company is engaged in the development, production and marketing of medical devices for cardiovascular
surgeons. The products are specially made for the patients and have less side effects.
The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow
tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens
the operation time (Matrix P plus).
B·R·A·H·M·S Aktiengesellschaft B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the
diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400
employees, in the disease areas infectiology, thyroid, autoimmunity and cardiology on the basis of
our own patented biomarkers. Since October 2009 B·R·A·H·M·S is part of Thermo Fisher Scientific
Inc. (NYSE: TMO), the world leader in serving science.
Bavarian Nordic GmbH Bavarian Nordic A/S is a leading international biopharmaceutical company developing, producing
and marketing innovative vaccines to prevent and treat infectious diseases and cancer.
bbi-biotech GmbH In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for
all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In
addition, bbi-biotech develops components - in especially disposable ones - for the preparation
of a new generation of fermentors and bioreactors and offers consulting and planning services for
biotech projects, its implementation and services.
BEB BioEnergy Berlin GmbH Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower plants, Preplanning,
Feasibility Studies and Research activities in the field of renewable energies, Optimization
of the process in existing biogas plants
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
ac-discovery.com
analytisches-zentrumbiopharm.de
anatox.de
animox.de
aokin.com
aptares.de
argus-umwelt.de
asca-berlin.de
astrabiotech.de
atlas-biolabs.de
attomol.de
autotissue.de
brahms.de
bavarian-nordic.com
bbi-biotech.com
bebgmbh.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Companies
Bioanalyt GmbH BioAnalyt GmbH brings easy-to-use diagnostic tools to the front lines of food production and
processing as well as of global health programmes. BioAnalyt is developing, manufacturing, and
marketing on-demand diagnostic tests for a variety of analytic focuses. Our innovative work and
products have been awarded with several prizes. BioAnalyt GmbH is a spin-out of a university,
which is focusses on the investigation of nutrients in food and biological fluids.
Bioassays GmbH Service related to the development of medical in vitro diagnostic products. Basic science to clinical
development. Profiling of biomarkers in clinical trials.
Biochrom AG Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and others). They
are distributed to universities, industrial cell culture laboratories and industrial manufacturers.
Service is of special significance for users of cell cultures. Special media developments and production
optimizations are offered.
BIOCYC Gesellschaft für Biotechnologie
und Recycling mbH & Co.KG
Production of bio-chemicals, peptides, in-vitro-diagnostics, test-kits. Development of consumer
service for peptides and biochemicals.
BioGenes GmbH BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) development
company with outstanding problem solving capabilities specializing in challenging projects that are
carried out by an exceptionally experienced and interdisciplinary team.
Bioline GmbH Bioline GmbH develops, produces and markets innovative reaction agents which are essential for
scientists in all sectors of molecular biology. The product range also includes high quality nucleotides,
enzymes, DNA ladders and puffers. In addition to production, Bioline GmbH also conducts
research to develop innovative products to ensure that the company is always a development
leader and can satisfy customers' ever increasing needs.
BioMedion GmbH IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Archiving
and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of
Computerized Systems according to GAMP4/5
biorefinery.de GmbH Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, and proteins,
the biorefinery.de company has developed four complex product lines (Biorefinery systems)
which leads to a great number of valuable products with the help of chemistry and biotechnology.
BioRepro GmbH BioRepro is the first pharmaceutical company, whose core competency is the breeding of leeches
under controlled laboratory conditions for medical therapies. We concentrate on the establishment
of GMP breeding procedures and will be able to provide leeches with standardized quality while
equally allowing scalability to supply medical demand. Additionally, through the re-initiation
of fundamental research, we will gain deeper understanding of further potential in medical and
cosmetic treatment areas.
BioS Biotechnologie Schönow GmbH Embryo transfer and associated biotechnologies in animals. Service, training and research in this
field.
BIOSYNTAN Gesellschaft für
bioorganische Synthese mbH
Biotech-Laboratorium für Environment
BLE GmbH
BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified peptides
(e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the
conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal
antibodies.
Development of detection systems which are able, economically and rapidly, to detect oil contaminations
and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH
is concerned with the biological degradation of oil contaminations and the development of a set of
bio-preparations consisting of different bacterial strains which break down oil.
BIOTECON Diagnostics GmbH BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular and
microbiology for the last 11 years. We focus on development, production and marketing of PCRbased
rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage
industry as well as for producers of pharmaceuticals and cosmetics.
BioTeZ Berlin-Buch GmbH p Services (Custom Oligonucleotide synthesis, Immuno affinity columns) p Development of Enzyme
Immunoassays, e.g. for Therapeutic Antibodies p R&D (Low Density Biochip)
BIOWORX-Biotechnologielabor
Thomas Grimm
BIOWORX offers services in the fields of contract research for customer-specific Biotransformations,
the screening, isolation and production of Biocatalysts from microorganisms and plants and
the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with
enzymes for customer in kg scale.
BiRDS Pharma GmbH BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field of drug
development to pharmaceutical and biotech companies, including management of drug development
projects as well as consulting services. The company also pursues own drug development
projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug
candidates derived from Atomic Substitution Technology (AST).
breecon GmbH The breecon GmbH is an innovative service company in life science with focus on green biotechnology.
The objectives of the company are consulting, application and mediation of biotechnologicalanalytical
services as well as their development and marketing. The breecon GmbH offers his services
to plant breeders and companies of the industrial biotechnology and supports the utilization
of genetic diversity in the context of SMART breeding.
bioanalyt.com
Biochrom.de
quartett.com
biogenes.de
bioline.com
biomedion.com
biorefinery.de
biorepro.de
bios-schoenow.de
biosyntan.de
bc-diagnostics.com
biotez.de
bioworx.de
birdspharma.com
breecon.com
65

66
Biotech Companies
BST Bio Sensor Technology GmbH BST develops and produces biosensors to provide high quality analysis at moderate prices. In 1982
BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe
and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since
2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments.
caprotec bioanalytics GmbH caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows to separate and identify
proteins based on functionality. For many applications, CCMS is clearly superior to conventional
methods - thus addressing an unmet need in the proteomics research community. The company
develops caproKits for proteomics research and plans to enter into collaborations with the pharmaceutical
industry for small molecule / drug optimization and development.
Capsulution Pharma AG Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The company
applies its worldwide-patented so-called LBL-Technology ® . Based on their minute size, their
functionality and their highly reproducible production process the capsules can be used for a multitude
of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be
made to function in a manner to suit the intended application, and can be given the appropriate
biochemical, electrical, optical and magnetic properties as required by the customer.
Cavira GmbH Cavira is active in the field of infectious diseases and oncology. For the time being two products are
in preclinical stage with encouraging in vitro and in vivo data. One product is a derivate of a well
known chemotherapeutic. The other one is combination therapy based on the amino acid depleting
enzyme Histidinase with broad potential in both, oncology and infectious diseases. Research
and development are conducted in cooperation with very well known universities or contract
research organizations.
celares GmbH Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of Biopharmaceuticals
with polyethylene glycol in order to substantially improve pharmacological properties.
Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dispersed,
highly branched polyethylene glycol based reagents. Additionally celares offers customized
PEGylation solutions as well as synthesis of customized PEG-reagents.
CellServe GmbH CellServe is a service provider for research groups in regenerative medicine, especially in the
production, functional characterization and monitoring of cells as therapeutic agents and research
tools, each in accordance with the most recent regulatory guidelines and cGMP standards. With its
services and products, the company fills an important gap in the conversion of applied treatment
concepts from research into marketable products.
CellTrend GmbH Celltrend is certified according to ISO 9001, ISO 13485 and GMP - Cell culture systems for research
on active substances (bioassays, preclinical research, for quality control) - Development and
production of antibody-based detection systems (ELISA) - Chemosensitivityassay for optimisation of
chemotherapy (tumor patients)
chemicell GmbH chemicell develops and produces magnetic, fluorescent and coloured nano- and microparticles,
reactive fluorescent dyes and special chromatography-materials for the separation or detection of
cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.
Chipron GmbH Chipron GmbH specializes in production and distribution of array based detection systems for DNA
/ pathogens
CHIRACON GmbH chiracon is a qualified partner to develop chiral intermediates at a constant high quality for
innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer
support through expert knowledge and key technology to meet your increasing needs. Our core
competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse
raw material source for high-level API production and development.
CMZ-Assay GmbH Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and their
isoforms, exclusively for research purposes.
co.don AG co.don ® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medicine/Tissue
Engineering. Since 1997, co.don ® AG has developed, manufactured and distributed
human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and
intervertebral discs.
CompoundSelect CompoundSelect offers customized compound databases, consisting of e.g. medicines, natural
compounds or scents.The databases are provided with a variety of screening options, a comfortable
usability, physico-chemical properties and additional information such as availability, supplier and
functional features for each compound.
CONGEN Biotechnologie GmbH CONGEN is specialized in food testing by molecular analytics based on DNA and RNA detection.
CONGEN has been a pioneer for over a decade in the development and application of food and feed
analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service.
Our mission is to serve the food industry with an excellent service and with standardized and reliable
test kits in order to realize highest possible food safety and food quality.
CREATOGEN Laboratories GmbH Development of vaccines for application in veterinary and human applications.
Cyano Biofuels GmbH The company focuses on the biotechnological use of cyanobacteria, especially the development and
optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical
feedstocks.
Cyano Biotech GmbH Cyano Biotech identifies and characterizes natural products from cyanobacteria and optimizes their
pharmacological activities employing a biocombinatorial approach. The company conduct further
development of identified lead structures till the preclinical phase.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
bst-biosensor.de
caprotec.com
capsulution.com
cavira.de
celares.com
cellserve.de
celltrend.de
chemicell.com
chipron.com
chiracon.de
cmz-assay.com
codon.de
bioinformatics.charite.de/
compoundselect
congen.de
cyano-biofuels.com
cyano-biotech.com

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Companies
Diaglobal GmbH Development, production and distribution of in-vitro-diagnostics for analytical purpose and the
distribution of medical products.
DIZG Deutsches Institut für Zell- und
Gewebeersatz gemeinnützige GmbH
Dr. Götz Verfahrenstechnik Biotechnik
Umwelttechnik
DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preservation as
well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics,
teaching and research organisations. Further service is culturing of skin cells (keratinozytes) for
serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell
cultures to help avoid experimentation with animals e.g. in the cosmetics industry.
diaglobal.de
dizg.de
Contract research and contract manufacturing using bacteria, yeasts and fungi. drgoetz.de
Dr. Lerche KG Innovative company engaged in development, production and marketing of specialized microcapsules
for bio- and medical technology p Development and production of novel DNA-Purification-
Kits with proprietary technology p Production and marketing of microcapsules (LUMiTainer),
microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards)
p Encapsulation of cells - Contract analysis for characterization of microcapsules, porous membranes
and hollow fibres
Dr. Otto GmbH p Research and development of ecological products, process development, production and marketing
p Production and refinement of plant ingredients p Operation of an analytical laboratory
for renewable resources and chemical analysis
Dr. Rölleke Labor für Genetische
Analytik GmbH
Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area of food
safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private
sector.
DSM Biopract GmbH Service and Additives (enzymes, trace elements, microbes) for biogas and waste water sludge treatment.
Enzyme analysis in Food and agriculture industry.
durakult durakult GmbH discovers and optimizes starter cultures and novel whole-cell catalysts for customers
in the food, chemical and renewable energy industries. durakult provides a new technology to
explore microorganisms from natural untapped biodiversity for industrial applications. durakult
stabilizes genetically manipulated cells which show weak growth or unstable metabolic properties
and fits them to industrial purposes.
lerche-biotec.com
dr-otto-gmbh.de
dr-roelleke.de
dsmbiogas.com
durakult.com
E.R.D.E.-AAK-Diagnostik GmbH E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial purposes. aak-diagnostik.de
Eckert & Ziegler AG Eckert & Ziegler Strahlen- und Medizintechnik AG, headquartered in Berlin, is a globally active
isotope technology company and holding company for a number of specialised subsidiaries that
process radioisotopes as well as develop, manufacture and sell isotope technology components,
medical technology equipment and related products.
EMP Biotech GmbH Production of fluorescent dyes and chemiluminescent reagents. Contract chemical synthesis of
small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides.
Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for
DNA synthesis.
Epigenomics AG Development and commercialization of innovative molecular diagnostic test products based on DNA
methylation for cancer screening and for cancer specialty applications.
Epiontis GmbH Establishing methylation fingerprinting as Gold Standard for quality control in Regenerative Medicine
and Immunomonitoring.
Epo Experimentelle Pharmakologie &
Onkologie GmbH
Eurovir Hygiene-Institut/
Dr. Thraenhart
The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer is a specialized
market segment. Using the equipment available, all experimental and animal experiment
techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for
the drug development section of large pharmaceutical companies, for partners from the Biotech
industry and for research institutions.
Laboratory service for testing the efficiency of products against viruses (virucides) and of processes
for inactivating or eliminating viruses (virus safety)
EVESTRA GmbH EVESTRA is a newly founded biotech company focusing on developing female health products.
The company's expertise resides with steroid chemistry and biology. EVESTRA's product pipeline
includes products for contraception, hormone replacement therapy, gynecological disorders and
hormon dependent cancers.
Evotec AG Evotec is a leader in the discovery and development of novel small molecule drugs. Both through
its own discovery programs and through research collaborations, the Company is generating the
highest quality research results to its partners in the pharmaceutical and biotechnology industries.
F.A.T. Forschungsinstitut für
Antioxidative Therapie GmbH
Measuring instruments and kits for evaluating the antioxidant properties and the degree of oxidative
damage in biological substrates
fermtec GmbH Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermentation,
innovative foods and beverages and auxiliary substances for the food industry
ezag.de
empbiotech.com
epigenomics.com
epiontis.com
epo-berlin.com
eurovir.de
evestra.com
evotec.com
antioxidant-research.eu
fermtecgmbh.de
Ferropharm GmbH Development of very small super para-magnetic nano particles as contrast agent for MRI ferropharm.de
FILT Lungen- und Thoraydiagnostik
GmbH
Development of innovative, non-invasive diagnostic methods in the area of respiratory diseases
and allergies
filt.de
67

68
Biotech Companies
Formula Pharma GmbH p Galenic and chemical development-Import, manufacturing, quality control (re-test) and release
of clinical supplies and market products p GMP-certificat / Manufacturing license in accordance
with §13 AMG
GA Generic Assays GmbH Development, manufacturing and distributing of in-vitro-tests, focussing on autoimmune diseases,
hereditary and infections diseases.
Gene Analysis Service GmbH We offer quick and complete molecular biological diagnostic and analysis service for hospital,
research and industry. Our service includes nucleic acid isolation, PCR-amplification and DNAsequencing.
We design custom protocols and are specialized in the analysis of rare genetic diseases
that require complete exon sequencing.
GenExpress Gesellschaft für
Proteindesign GmbH
GenExpress is a flexible company providing services in molecular biology. For over a decade we
have successfully worked for customers in clinical laboratories, research institutions and the
industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins,
evaluation of LightCycler ® assays, furthermore production of internal controls and standards for Real
Time PCR systems, also cloning, expression and purification of proteins.
GILUPI GmbH GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer market.
The company is developing an innovative new diagnostic product based on nanotechnology. Our
goal is to catch specific cells, which can be found only in very low concentration in the blood. The
first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberration
out of maternal blood. The second application will focus on the early diagnosis of cancer.
GlucoMetrix PVS GmbH The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-aftermath.
At the foreground of research and development is enhancing the quality of life of diabetics.
In addition, the life science company develops some IT-based diagnostic procedures and medical
devices as well as biopharmaceuticals and other highly effective products in order to raise the
quality of life of diabetics sustainably.
Glycon Biochemicals GmbH Production of carbohydrate components used for the synthesis of new pharmaceutical compounds
or diagnostics
Glycotope GmbH Glycotope is a leading company in glycomics and immunotherapeutics. It has developed novel
therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological
entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables
us to offer the entire process of biopharmaceutical development with a dedicated focus on our
unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical
grade material.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
formula-pharma.de
genericassays.com
gene-analysis-service.de
genexpress.de
gilupi.com
glucometrix.de
glycon.de
glycotope.com
Götz Protein Engineering Offering a wide range of protein technology up to the final purified protein goetz-protein-engineering.
de
HC Berlin Pharma AG Pharmaceutical products, intellectual property, patents, know how and expertise have been compiled
in the new HC Berlin Pharma AG. The uniqueness of the various products especially the new
malaria treatment will generate immense revenues based on the high market demand.
HealthTwiSt GmbH HealthTwiSt is a service provider for "Genetic Contract Research" in the fields of Functional Genomics,
Pharmacogenomics, Proteomics or Functional Food / Nutriceuticals. In particular, HealthTwiSt
is offering access to extensively characterized human subjects and samples as well as prospective
studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore,
database development, data management and statistical analyses for clinical projects are provided.
HF Biotec Berlin GmbH Development, selling and operating of digestion plants using liquid substrates of industrial and
agricultural provenience, Development and operating of combined plants to upgrade biogas into
bio methane useable in public gas grids with parallel production and selling of high quality PCC,
Development of innovative biotechnological processes and plants.
Human BioSciences GmbH The biotech-company Human BioSciences Inc. is specialized in manufacturing and distribution of
modern collagen based wound and skin care products.
HUMAN GmbH For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and manufactures
in Germany laboratory diagnostic products for the world market. HUMAN stands for quality
and service in over 160 countries. In our new competence centre for autoimmune diagnostics, an
expert team of highly specialized scientists and technicians develop and produce the IMTEC product
line, a range of high-quality autoimmune diagnostic products. Further innovative products are to
be launched soon!
icon biotech Icon biotech is an innovative biotechnology company, which uses the extraordinary characteristics
of Ciliates for the development of bio-analytical and toxicological model systems.
hcberlinpharma.ag
healthtwist.de
hf-biotec.com
HumanBioSciences.de
human.de
icon-biotech.com
ifp Institut für Produktqualität GmbH Laboratory and competence centre for state-of-the-art food and feed analysis produktqualitaet.com
IGV Institut für Getreideverarbeitung
GmbH
The range of services offered by the Biotechnology Division of the private research IGV GmbH institute
is based on 25 years of experience in R&D for the cultivation of phototropic micro-organisms.
Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and
cosmetics and energy industry provide the fundament for innovative, market-oriented developments.
In focus are development of photo bioreactor technology and active substances from algae.
igv-gmbh.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Companies
IKDT Institut Kardiale Diagnostik und
Therapie GmbH
IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories on Viral
Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is performing
a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a
limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to
start an efficient, pathophysiologically based causal therapy.
ILBC GmbH Research, consulting, production, trade & services in the areas biology, molecular biology and
protein chemistry - Expression and production of antimicrobial peptides
imaGenes GmbH RZPD spin-off, premier service center for genome research in Europe, provides one of the largest
clone collections in the world via its clone search engine GenomeCube ® . Certified Service Provider
for comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms, high
throughput RT qPCR, complete portfolio of Next Generation Sequencing services. ISO 9001:2008
certified.
In.vent DIAGNOSTICA GmbH in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-oriented provision,
processing and distribution of biological raw material for development and production of
diagnostics and control material. We are your reliable partner for the customised development of
assays for medical in vitro diagnostics.
inbion GmbH inbion GmbH provides services to support research in the interface between university, students
and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-efficiently
to competent teams. Cooperation with research groups in the university is also facilitated, so
that targeted knowledge transfer can take place here.
ikdt.de
imagenes-bio.de
inventdiagnostica.de
inbion.de
Innovative Optische Meßtechnik Fluorescence Assay Solutions and Instrumentation (Microplate Readers) iom-berlin.de
Institut für Medizinische
Molekulardiagnostik (IMMD)
Institut für Molekular- und
Systemmedizin I.M.S.M. GmbH
Gene tests for prenatal, predictive and tumor -diagnostics immd.de
Scientific-practical works in the area of System medicine with the purpose of the patenting of new
treatment methods, e.g. to the treatment of diabetes. International cooperation in this area.
Invitek GmbH Invitek, a member of the STRATEC group, is a globally active provider of innovative system solutions
for nucleic acid sample collection, stabilization, and both manual and automated purification from
any sample type. Since 1992 the company is internationally respected for its outstanding and high
performance technology platforms and offers a broad spectrum of superior products for molecular
diagnostics, drug discovery and Life Science research.
InVivo Biotech Services GmbH As a contract manufacturing company (CMO) Invivo offers a wide range of services: the development
and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical
use (endotoxin-free antibodies and compliant documentation), cell line development and transient
transfection. We are an ISO9001:2000 certified company.
Jerini AG Jerini is a pharmaceutical company based in Berlin, Germany. Shire Limited's German whollyowned
indirect subsidiary Shire Deutschland Investments GmbH currently holds 100 percent of
Jerini's shares. Jerini is a subsidiary of Shire plc and a member of the Shire group of companies.
JPK Instruments AG JPK Instruments AG is a leading manufacturer of nanoanalytic instruments for the life sciences and
soft matter sectors. The company was the first to recognize the innovative opportunities of nanotechnology
for the biological, medical and pharmaceutical sciences and tailored its instruments
platform to the requirements of this area of application. JPK implements comprehensive solutions
for high-resolution imaging, power measurements, nanomanipulation and lithography.
JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH, a wholly owned subsidiary of Jerini AG, is a DIN EN ISO 9001:2000
certified biotechnology company based in Berlin and a leading supplier of innovative peptidebased
services and products. JPT provides peptide arrays, peptide libraries and specialty peptides.
Klinomed GmbH Development of new technologies for manufacturing bio-active nano particles / development of
therapeutic formulations based on nano particles
KNAUER - Wissenschaftliche Gerätebau
Dr. Ing. Herbert Knauer GmbH
L.U.M. Gesellschaft für
Labor-, Umweltdiagnostik &
Medizintechnik mbH
KNAUER UHPLC and HPLC systems as well as columns are used in research and development, quality
control and production plant laboratories around the world. Customers are typically governmental
and industrial organizations as well as universities. Fields of application are wide-ranging and
include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as
environmental analysis. With our biochromatography solutions we focus on high resolution separations.
Analysis, diagnosis and sensor technology as well as stability, rheology and segregation behavior of
dispersions
invitek.eu
invivo.de
jerini.com
jpk.com
jpt.com
klinomed.de
knauer.net
lum-gmbh.de
Lab4you GmbH Development and distribution of lab devices for biochemistry, biotechnology and medical analytic lab-4-you.com
LAROVA Biochemie GmbH Research, development and production of nucleotides, nucleosides, oligonucleotides in natural
and modified forms
larova.com
LGC Production of calibration substances for purity testing of drugs mikromol.de
69

70
Biotech Companies
LGC Genomics LGC Genomics (formerly AGOWA genomics) is the division of LGC with specific expertise in high quality,
cutting-edge genomic and related services and products.LGC Genomics delivers:p Next generation
sequencing services p DNA sequencing- Genomics services p Nucleic acid extraction services
p DNA extraction products. LGC is an international science-based company and market leader in
analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).
Limetec Biotechnologies GmbH The core competence lies in the development of high-speed and high-quality proof systems for the
detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products
are marked with the CE-Certificate. The second area of expertise is the creation of communication
networks which connect out-patient and hospital patient treatments, intensify data exchange and
provide information to all health institutions, thus establishing partner relationships between
them.
MagForce Nanotechnologies AG MagForce has developed a new process for local treatment of tumors – the Nano-Krebs ® therapy.
Temperatures between 41°C and 70°C can be generated within the tumor. The method is based
on the principle of direct, minimally invasive addition of magnetic nano-particles into the tumor
and their subsequent heating in a magnetic alternating field. Treatment has been tested in clinical
studies since 2003.
Marinpharm GmbH Development and marketing of genetically altered cell lines on the basis of new fluorescence markers.
MedInnovation GmbH MedInnovation GmbH has developed a new method and a special ESR-analyser, which for the first
time allows a simple routine laboratory test for evaluation of functional characteristics of plasma
proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology
(mobility of molecular structure).
Medipan GmbH Development, manufacturing and international distribution of radioactive (125J-IRMA) and nonradioactive
(Elisa) in-vitro diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid
and Diabetes Typ 1, automated interpretation of cell-based immunofluorescence tests by the
AKLIDES system.
MerLion Pharmaceuticals GmbH The business purpose of the Company is the research, production, optimization and the development
by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious
diseases
Merz Pharmaceuticals GmbH
Standort Potsdam
Merz is one of the leading research-based health care companies. Merz Pharmaceuticals has
achieved a leading position in Alzheimer’s research with the world’s first drug for the treatment
of moderate to severe Alzheimer’s disease. With high quality products from tetesept ® and Merz
Spezial ® , Merz is making a key contribution to health and wellbeing.
Metabolomic Discoveries UG Metabolomic Discoveries is an analytical service and research company. We provide mass spectrometry
based metabolite profiling and fingerprinting of biological material, as well as single
compound measurements.
metanomics GmbH Metabolite Profiling for identification of gene function relationship in plants, metabolite biomarkers
and metabolic networks
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
agowa.de || lgc.co.uk
limetec-biotechnologies.de/
magforce.com
marinpharm.com
medinnovation.de
medipan.de
merlionpharma.com
merz.de
metabolomicdiscoveries.com
metanomics.de
metanomics Health Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition metanomics-health.de
MetrioPharm AG MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new and
innovative medicines.
mfd Diagnostics GmbH The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development company
for diagnostic and therapeutic application of innovative laser technologies. The main advantages
of the developed technologies are the non-/minimally-invasive measurement methods, the nonartificial
approach and the possibility of real-time measurement. Therefore, those are promising
tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal
surveillance.
MicroDiscovery GmbH MicroDiscovery GmbH is a leading provider of high quality software for biomolecular research,
innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a
strong track record in creating software systems in accordance with relevant regulatory directives
for the life science and IVD industry. Customised services ranging from biostatistical data analysis
to bioinformatical design and support of complex research projects complete the product line of
MicroDiscovery.
microparticles GmbH Development, manufacture, surface modification and characterization of mono-disperse polymer
particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylatebased
polymer particles, microparticles GmbH has launched new melamine resin particles on the
market with exceptional chemical and physical qualities. The main areas of application are in
particle measurement technology, medicine, biochemistry and microelectronics etc.
Mikrobiologisches Labor
Dr. Th. Bernhard GmbH
Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, DAC-
PL-0302-04-00, EN 17025. Accreditation according to VDI 6022
Minerva Biolabs GmbH Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for contamination
control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is
also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors
ensure that our products are available worldwide, quickly and at a good price.
metriopharm.com
mfd-diagnostics.com
microdiscovery.de
microparticles.de
mikroberlin.de
minerva-biolabs.com

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Companies
mivenion GmbH mivenion is a life-science company founded in Berlin aiming on the development and commercialization
of diagnostic and therapeutic products. The company is built on two innovative
technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid
arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion´s first
product on the market.
molConcept GmbH We offer computational drug design, rational drug design, and efficient simulation algorithms for
molecular systems
Molnar-Institut für angewandte
Chromatographie
Molnar-Institute, established in 1981, offers you a complete scientific and technical service for all
problems concerning HPLC-analytics. We develop for you the HPLC-solution and we offer detailed
HPLC-courses and show you, how to develop robust methods and how to save time. We supply and
implement the DryLab-software and train your coworkers. We assist you in the selection of the
proper instruments, its installation and use.
MOLOGEN AG MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the development
of novel DNA-based medicines against cancer and vaccines against infectious diseases. The proprietary
platform technologies MIDGE ® and dSLIM ® build the foundation for all business activities. The
company was founded 1998 and was one of the first biotechnology companies to go public.
MolTech Molekular Technology GmbH Custom research and process development in the area of bioluminescence, production of restrictase
and photo proteins
Nano Access Technologies Limited The company addresses the combined access to key technologies such as life science and nanotechnology.
As a first product, a low cost AFM for operation with so-called active cantilevers has
been developed. Besides this, functionalized cantilevers for future biosensors are another focus of
the company.
Nanolytics Gesellschaft für
Kolloidanalytik mbH
we are a contract laboratory specializing in the physico-chemical characterization of pharmaceutical
proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are
Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as
spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC).
nanopartica GmbH Nanopartica GmbH optimizes existing products of other companies, but are also developing new
products and materials. In particular, companies in surface-, bio-, and medical-technology can
benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules
(drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change
the guests' properties and expands its scope.
nanoPET Pharma GmbH As a technology and service provider to the biopharmaceutical industry nanoPET focuses on the
R&D, production as well as marketing of innovative drug substances for diagnostic imaging based
on novel nanoparticular materials. nanoPET offers consulting and contract research services, preclinical
contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical development
of its patented core technology of inorganic nanoparticle PET tracers.
NovaBiotec ® Dr. Fechter GmbH Microbiological and chemical investigations, in particular of soil, water and air samples, planning
/ inspection of sanitation, in particular analytics and sanitation support for mould and dry rot,
incl. education in this field. Delivery of production auxilliaries and support for biogas plants with
biological treatment processes incl. application, insulation and preservation of enzymes. Research,
development and marketing of test kits for breweries and malthouses.
New Medical Enzymes AG Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on
therapeutically useful enzymes. The company has developed a new product family based on amino
acid depleting enzymes. This unique approach is highly effective against cancer - the major target
market of Medical Enzymes AG.
Novamol Development and manufacture of human and veterinary food supplements and health-enhancing
products
novojoint R&D of a new therapy approach for the treatment of severe, inflammatory diseases of the joint and
for the support of wound healing after injuries of the skin and bones in man as well as animals.
The concept is based on the development of smart gene constructs, which allow the inflammation
controlled release of suitable therapeutic proteins at the site of damage/repair. We aim to provide
our therapy for three target markets: 1, Small Animal Clinics, 2. Equine Clinics, 3. Human Medicine
NOXXON Pharma AG NOXXON Pharma is a private clinical-stage biotechnology company focusing on the development of
its proprietary Spiegelmers ® for treatment of inflammatory diseases and hematological indications.
The company targets various disease areas: diabetes-related complications with an inflammatory
component, autologous stem cell mobilization as blood cancer support therapy, and anemia of
inflammation. In addition NOXXON has partnered with the pharmaceutical industry, including Eli
Lilly and Roche.
NutriNeu GmbH NutriNeu GmbH develops a new generation of pre and probiotics. First products are based on
microorganisms that were isolated with our proprietary GlycoScreen technology (antibody directed
isolation of microorganisms expressing specific carbohydrate structures). Besides developing own
products, NutriNeu GmbH offers services in the fields of microbiology, process development and
Glycoanalytic. NutriNeu GmbH also helps customers to investigate the probiotic properties of their
microorganisms.
ocCure GmbH ocCure´s goal is to improve the diagnostics and therapy of ovarian cancer. The young biotechnology
company focuses on the discovery, validation, and marketing of novel genetic features using
established analytical technologies.
mivenion.com
molconcept.com
molnar-institut.com
mologen.com
mt-berlin.com
nano-access.com
nanolytics.de
nanopartica.com
nanopet-pharma.com
novabiotec.de
medical-enzymes.com
novamol.com
novojoint.de
noxxon.com
oc-cure.com
71

72
Biotech Companies
opTricon Entwicklungsgesellschaft f.
optische Technologien
opTricon develops and produces mobile readers for quantitative analyzes of Immunoassays for
Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are
components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops
the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV
Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.
ORGANOBALANCE GmbH ORGANOBALANCE GmbH is specializing in microbial strain development and microbiological
screening. Tapping into the natural potential of beneficial microorganisms and probiotic cultures,
ORGANOBALANCE develops new biological products in the areas of nutrition, cosmetics, preventive
health care and industrial biotechnology. In its development activities, the company draws on its
own collection of microorganism strains suitable for food applications and its own OASSYS ® screening
systems.
OSSOGEN Biopharm GmbH OSSOGEN Biopharm GmbH is dedicated to the development of recombinant Parathyroid Hormonebased
medicines for various indications. The company is a Joint Venture between German BDD/
CCDRD Group and Korean Green Cross Corporation.
ovalehn GmbH Production and application of specific recipes -containing IgY for diagnostics and oral, passive
immune therapy
peptides&elephants GmbH Custom synthesis of peptides and peptide libraries - Development parallel Synthesis technologies -
Distributor of Peptide Synthesis Automation
PharmaSol GmbH Modification of ingredients or introduction of new metabolic pathways in plants with gene-technology
methods
Pharmicell Europe GmbH p Manufacturing of stem cells from bone marrow and adipose tissue for therapeutic and plasticaesthetical
application p Manufacturing of adult stem cells for research (mesenchymal stem cells,
endothelial precursor cells) p Banking of stem cells
PlasmaChem GmbH PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in nanomaterials,
plasma- and ultra-thin film technologies. The company manufactures nano-coated medical
implants (stents), nanomaterials, additives for metal plating (applied e.g. by Siemens AG), new
additives to engine oils on the base of nanodiamonds and other industrial nanoproducts.
PolyAn, Gesellschaft zur Herstellung
von Polymeren für spezielle
Anwendungen und Analytik mbH
preclinics Gesellschaft für präklinische
Forschung mbH
PolyAn is specialised in Molecular Surface Engineering (MSE) and Surface Molecular Imprinting (SMI).
PolyAn's proprietary MSE-technology platform is used for the production of biochips (microarray
slides), microparticles and nanoparticles (fluorescence encoded polymer microspheres) and highly
selective membranes, e.g. for Pervaporation, organophilic Nanofiltration. For oligo-, peptide and
protein microarrays we offer functionalised glass and polymer slides.
preclinics is a commercial cooperation partner for preclinical research and development. As a
competent, creative and experienced partner preclinics investigates pharmaceutical substances,
therapeutic methods and proceedings as well as medical products during the preclinical phase.
Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species.
ProBioGen AG ProBioGen is a specialist in mammalian cell development, process engineering and GMP manufacturing
of biopharmaceutical drug substances. Offering state-of-the-art contract development
and manufacturing services as well as access to proprietary cell lines (AGE1.cell lines(R)) for the
manufacturing of biopharmaceuticals and vaccines.
ProteaImmun GmbH ProteaImmun GmbH offers human proteases, ELISA, enzyme and antibody. ProteaImmun's expertise
in the recombinant protein expression, especially in human proteases and in the development of
antibodies and modern methods of detection and analysis of proteins, enables us to offer customized
solutions and support with single components as well as with complete molecular diagnostic
systems.
PROTEKUM - Umweltinstitut GmbH
Oranienburg
We plan to eliminate fluid und solid waste products in a manner which is compatible with environment
protection. Our methodology is largely based on painstaking analysis. We use modern
equipment and scientific methods. Protekum offers high-quality products and services in environmental
analysis redevelopment.
Proteome Factory AG Biomarker & target discovery, validation, analysis of food and ingredients, absolute quantification
of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE
and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane proteomics,
protein identification, characterization of proteins and peptides (PTMs, e.g. phosphorylation,
glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver
staining kit etc.
provitro GmbH Provitro combines more than ten years of experiences in commercialisation of cell culture technologies,
Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the
Pathological Institute of the Charité, Berlin. Based on a quality management system according to
ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in-vitro
diagnostics and state-of-the-art services but also with individual solutions for their specific
requests.
Rapidozym Gesellschaft für Laborhandel
und DNA Diagnostika mbH
Expertise of cell biologists cell manufacturing and clean room technology specialists. Focuses
on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic
surgery.
rennesens GmbH Research and development of myocardial infarction diagnosis, production and worldwide distribution
of the fastest and earliest AMI Test with the heart attack marker h-FABP.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
optricon.de
organobalance.de
ossogen.com
ovalehn.de
peptides.de
pharmasol-berlin.de
pharmicell.eu
plasmachem.com
poly-an.de
preclinics.com
probiogen.de
proteaimmun.de
protekum.de
proteomefactory.com
provitro.de
rennesens.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Biotech Companies
Revotar Biopharmaceuticals AG Revotar develops innovative small molecule drugs (SMD) for the treatment of chronic inflammatory
disorders such as, chronic obstructive pulmonary disease (COPD), Acute Lung Injury (ALI/ARDS)
and ischemia / reperfusion. With its drug candidate bimosiamose, Revotar has the worldwide most
advanced pan-selectin-antagonist in clinical development in its product pipeline.
RiNA GmbH RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukaryotic cell
lysates. A synthesis service is realised in RiNA's own laboratories and complements the EasyXpress
Kits (Qiagen). The purchase of Roche´s RTS-products enables RiNA now to be a key player in the
field of cellfree biosynthesis with a large variety of products. Another research focus is the development
of aptamers (DNA and RNA) for biosensors.
RIPAC-LABOR GmbH RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, pigs and
cattle, but also in other farm and domestic animals. The company uses pathogen differentiation
to provide quick and effective methods for fighting pathogens. It performs resistance tests and
epidemiological analyses and also focuses on producing herd-specific vaccines.
RNAx GmbH RNAx specializes in RNA-Interference services. It offers functional validations of si- and shRNAs,
target validation studies using automated high throughput approaches, as well as whole genome
screens with automated assays.
Roboklon GmbH Distribution, Marketing and Development of Products for Molecular Biological Research and Genetic
Engineering.
ROVALAB GmbH Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our high quality
critical raw materials and reagents such as DNA Polymerases and dNTPs are designed to help you
successfully and rapidly solve your scientific and manufacturing tasks.
Royal Biotech GmbH Royal focuses on developing, manufacturing and marketing innovative kits, portable or microstructured
systems, and the next generation of diagnostic chips for near real-time environmental,
food safety, disease and laboratory diagnostics
Scienion AG Scienion is a life science company in the markets of dispensing systems and microarray technologies.
The product portfolio comprises hardware, consumables and services. Scienion's leading
product is the sciFLEXARRAYER dispensing system, available in a product line of six size versions.
The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and noncontact
micro drop delivery in the picoliter to microliter range onto a variety of carriers.
Sepiatec GmbH Production, development and sales of automated HPLC machines for high-throughput purification
and fractioning of complex substance compounds
Seramun Diagnostica GmbH Seramun offers peptide synthesis, purification and conjugation of proteins, production of antibodies,
customer research, In-vitro Diagnostics. We focus on the development and production of
enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune disease of
the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays
and as membrane immunoassays, as well as development of ready-to-use substrate solutions and
for protein stabilizers.
SGS INSTITUT FRESENIUS Berlin
GmbH & Co. KG
SIFIN Institut für Immunpräparate
und Nährmedien GmbH Berlin
Analytical laboratory services and consulting for development, production and quality control of
drugs
Development, production and purification of monoclonal antibodies for use in diagnostics. Development
and production of blood grouping reagents, Serafol ® bedside cards and test reagents for
serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and production of culture
media for microbiological diagnosis.
Signature Diagnostics AG Signature Diagnostics is dedicated to the discovery, validation and commercial development of
novel diagnostic products that predict outcome and drug response in patients with colorectal
cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient
selection and stratification based on molecular gene signatures will soon become an important
component of routine cancer treatment.
Silence Therapeutics AG Silence Therapeutics has developed novel, proprietary short interfering RNA ("siRNA") molecules,
AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show
increased stability against nuclease degradation. In addition, the Company has developed a proprietary
systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted
diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.
revotar.de
rina-gmbh.eu
ripac-labor.de
RNAx.de
roboklon.de
rovalab.com
royalbiotech.de
scienion.de
sepiatec.com
seramun.com
institut-fresenius.de
sifin.de
signature-diagnostics.de
silence-therapeutics.com
SONEX GmbH Biotechnology processes for product synthesis. Byproduct processing and reduction of contaminants sonexgmbh.de
Speziallabor für angewandte
Mikrobiologie
Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking water,
foodstuff, monitoring in clean rooms.
Strix Diagnostics GmbH Strix Diagnostics is a medical diagnostics company specializing in customized development of certified
analytical systems for multiparameter in-vitro diagnostics.
Surflay Nanotec GmbH Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is specialized on
coating colloidal and planar materials with functional films. Key technology is the patented
LbL-Technology ® with polymers. Applications are in the fields of separation materials, pigment
encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects
Surflay offers an unique range of products of tunable multifunctional nano-or microparticles and
dye-labeled polymers.
slm-fiedler.de
strix-diagnostics.de
surflay.com
73

74
Biotech Companies
Thanares Thiede Analytik und Research
GmbH
Development, use and marketing of analytical process for diagnostic and therapeutic purposes.
Future business activities: detection process for bioactive substances in bodily fluids, isolation,
characterization and investigation of bioactive compounds from plants, in particular insoluble
proteins or low concentrations of proteins, development of low cost genetic systems for overexpression
and/or production of such proteins.
TIB Molbiol Syntheselabor GmbH In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In addition to
designing and synthesizing primers and probes for Real-Time-PCR assays, we develop and produce
LightMix ® kits for Roche Diagnostics LightCycler ® instruments, covering applications in Clinical
Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO
13485 certified.
TransTissue Technologies GmbH TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September 2001. With
more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technologies
have developed second-generation autologous tissue replacements, e.g. cartilage and bone
grafts. We are mainly concerned with inventions and the development of tissue engineering
products for regenerative medicine. We offer a broad panel of services in the field of regenerative
medicine.
Umwelttechnik Dr. Bartetzko GmbH Feasibility studies, development, planning, construction and operation of biotechnological plants
for groundwater, process water and waste water purification. Accredited microbiological laboratory
for the investigation of drinking water, groundwater, bath water, soils, anti-microbial active ingredients
and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German
infection protection act (Infektionsschutzgesetz).
VasoTissue Technologies GmbH The company is active in the field of product development for advanced medical therapies. For its
first product - the endothelialised vascular graft ("VasoGraft")- VasoTissue obtained a manufacturing
license in 2008. Currently, VasoTissue´s focus is on conducting its first clinical trial.
WITA GmbH WITA is a high technology service and product company specialized for protein and proteome
analysis using high resolution NEPHGE 2-DE (up to 410 mm x 300 mm gel size, up to 10.000
individual protein spots) and mass spectrometry. HPLC, Edman N-terminal sequencing, synthesis of
"tricky" unusual peptides
Zellwerk GmbH Zellwerk has developed and produces the Z ® RP platform comprising rotating bed bioreactor, GMP
Breeder, Control Unit and Sponceram ® cell carrier. In this culturing system cells grow tissue-like,
being embedded in their extra-cellular matrix. The technology opens new horizons for: - unique
3D cultivation of cells and stem cells - regenerative medicine and tissue engineering - gaining cells
or stem cells for therapeutic purposes - manufacturing implants - production of bio-pharmaceuticals
Zentrum für molekulare Onkologie
GmbH
Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K-RAS,
PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathology Development
of new biomarkers and analytical services for studies
Zytomed Systems GmbH Zytomed Systems´ focus is the development, production and distribution of antibodies and detection
systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ
hybridisation.
B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
tib-molbiol.com
transtissue.com
bartetzko.com
vasotissue.de
wita.de
zellwerk.biz
molekulare-onkologie.eu
zytomed-systems.de

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0
Research. For better health.
New drugs mean medical advances and better health. For over 150 years,
the people at Pfi zer have developed drugs to cure diseases and improve the
quality of life. And our research teams will continue putting forth every
effort to improve existing therapies and provide to doctors and patients new
preparations to treat to date incurablea diseases – for example, cancer,
Parkinson’s, and Aids. For better health.
75

Photo: © www.scienion.com
Small particles,
big ideas.
Inventive, leading, improving.
With more than 190 biotech companies employing
3,700 specialists, the Berlin-Brandenburg
capital region ranks among Europe’s leading
locations for biotech. You’ll find the entire
spectrum of the value chain, from substance
and process development to clinical research,
production and services. Companies can also
tap into the 3,000 highly qualified students
graduating each year from local life science
programs. Take advantage of Germany’s expertise
in the biotech and pharmaceutical fields.
www.biotop.de/business